Professor Jacob George

Professor of Gastroenterology & Hepatic Medicine
Medicine, Westmead Clinical School
Westmead Millennium Institute for Medical Research

Telephone +61 2 9845 7705
Fax +61 2 9635 7582

Website Related website

Map

Research interests

Professor George undertakes basic research on non-alcoholic steatohepatitis (NASH) and hepatic fibrosis. He is also researching the molecular and cellular basis for disease progression in chronic hepatitis C. He has published seminal papers on the central role of transforming growth factor beta (TGF beta) in fibrogenesis.

Selected grants

2014

  • NanoString nCounter Platform; deFazio A, Alexander I, Booth D, Byrne J, Christodoulou J, Clarke C, Cunningham A, George J, Graham J, Harman A, Liddle C, Mann G; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Hepatitis C infection: epidemiology, pathogenesis, and treatment; Lloyd A, George J, Beard M; National Health and Medical Research Council (NHMRC)/Program Grants.

2013

  • A pilot study of fenofibrate to improve hepatitis C virus treatment response - Australian Centre for HIV and Hepatitis Virology Research (ACH2); Douglas M, George J; Commonwealth Department of Health and Ageing/Health Surveillance Fund.
  • Building multidisciplinary research linkages - the University of Sydney and Chulalongkorn University Symposium; Meyer W, Dietz H, Freckelton L, George J, Gurney H, Hyett J, Snowdon J, Napathorn S, Chaisamran U, Chindamporn A, Srikiatkhachorn A; DVC International/IPDF Grant.
  • Characterization of ARL6IP5 in hepatitis C-related liver cancer; Qiao L, Douglas M, George J; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Adiponectin and cholesterol a driving force in NASH immunopathogenesis; George J, Hebbard L, Bendall L; National Health and Medical Research Council (NHMRC)/Project Grants.

2012

  • Developing functional research partnerships and student exchange, focused on relevant infectious diseases with the Eijkman Institute and Hasanuddin University, Indonesia; Yusuf I, Muljono D, Sorrell T, George J, Marais B, Douglas M; DVC International/IPDF Grant.
  • Small Rodent Airlaw Caging System; George J, O'Connell P, Cunningham A, Hawthorne W, Little D, Djordjevic J, Harris D, Hebbard L, Liddle C, Fletcher J; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2011

  • Exercise and liver fat reduction in pre-diabetes: moving beyond weight loss; Johnson N, Caterson I, George J, O'Connor H; Diabetes Australia Research Trust/Research Grants.
  • The role of endocannabinoids in chronic hepatitis C; George J, Douglas M; National Health and Medical Research Council (NHMRC)/Project Grants.
  • The role of adiponectin-mediated nitric oxide on portal hypertension and liver fibrosis; George J, Wang J; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Role of adiponectin in hepatic carcinogenesis; George J, Hebbard L; National Health and Medical Research Council (NHMRC)/Project Grants.
  • The effect of IL28B haplotype on hepatitis C virus infection and treatment response; Booth D, Ahlenstiel G, Stewart G, George J; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Novel molecular targets for treatment of hepatocellular cancer (HCC); Hebbard L, George J; Cancer Council New South Wales/Innovator Grant.
  • The BD Influx High Speed Cell Sorter; Cunningham A, George J, Rizos H, Clarke C, Reddel R, Kefford R, North K, Stewart G, Jones C, Tam P, Alexander S, Gottlieb D, Bradstock K, Bryan T, Booth D, Bendall L, Brilot-Turville F, Hebbard L, Cooper S, Wang Y, Wang X; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2010

  • The role of adiponectin receptors in liver fibrosis formation; George J, Hebbard L; National Health and Medical Research Council (NHMRC)/Project Grants.

2009

  • High-Throughput virtual microscopy and data warehouse system; Mann G, Schifter M, Balleine R, George J, Henderson B, Clarke C, Catchpoole D, deFazio A; Cancer Institute New South Wales/Equipment Grant.
  • Functional Genomics to Predict and Enhance Response to Interferon; George J, Suppiah V, Kingston D, Bahlo M, Yang J, McKay F, Booth D, Stewart G, Bahlo M; Australian Research Council (ARC)/Linkage Projects (LP).

2008

  • Epidemiology, prevention and management of liver cancer in NSW: Towards a strategic research partnership; Strasser S, George J, McCaughan G, Dore G, Liddle C, Strasser S; Cancer Council New South Wales/Strategic Research Partnership (STREP) Grants.
  • Epidemiology, prevention and management of liver cancer in NSW: Towards a strategic research partner; McCaughan G, George J, Strasser S, Dore G, Liddle C; Cancer Council New South Wales/Strategic Research Partnership (STREP) Grants.

2006

  • The Development of a National Centre for Clinical Islet Transplantation; Russ G, Wilson M, Dado M, Kay T, O'Connell P, George J, Hawthorne W; Juvenile Diabetes Research Foundation/Project Support.
  • Host factors affecting of Hepatitis C-associated liver disease; Thomas D, George J, Stewart G, Booth D; National Health and Medical Research Council (NHMRC)/Project Grants.

2005

  • Physiological basis of insulin resistance in chronic hepatitis C virus infection; George J; University of Sydney/Internal Research Grant Allocations - Faculty of Medicine.
  • Medical Foundation funding to support a NHMRC Program Grant No 358398. Entitled - Molecular & cellular pathogenesis of liver disease; Farrell G, McCaughan G, George J; University of Sydney/Internal Research Grant Allocations - Medicine.
  • Molecular and cellular pathogenesis of liver disease; George J, McCaughan G; National Health and Medical Research Council (NHMRC)/Program Grants.

2003

  • Centre of clinical research excellence to improve outcomes in chronic liver disease; Farrell G, McCaughan G, George J, Donaghy A, Strasser S, Strasser S, Donaghy A; National Health and Medical Research Council (NHMRC)/Centre of Clinical Research Excellence.
  • Molecular and cellular pathogenesis of nonalcoholic steatohepatitis: insights from human studies; George J, Leclercq I, Farrell G; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Cellular and molecular mechanisms of the profibrogenic effect of leptin in the liver; Farrell G, Leclercq I, George J; National Health and Medical Research Council (NHMRC)/Project Grants.

2001

  • Pathogenesis of liver injury and hepatic fibrosis in non-alcoholic steatohepatitis, NASH; Robertson G, George J, Leclercq I, Farrell G; National Health and Medical Research Council (NHMRC)/Project Grants.

2000

  • Hepatic fibrosis in non alcoholic steatohepatitis; George J; Clive & Vera Ramaciotti Foundation/Research Grant.

Selected publications

Download citations: PDF RTF Endnote

Edited Books

  • Qiao, L., Li, Y., Yan, X., George, J. (2012). Molecular Aspects of Hepatocellular Carcinoma. Sharjah: Bentham Science Publishers Ltd.

Book Chapters

  • Walker, S., George, J., Hebbard, L. (2012). Animal Models of Hepatocellular Carcinoma. In Liang Qiao, Yumin Li, Xiang Yan and Jacob George (Eds.), Molecular Aspects of Hepatocellular Carcinoma, (pp. 116-128). Sharjah: Bentham Science Publishers Ltd.
  • Pattullo, V., George, J. (2012). The Problem of Insulin Resistance and its Effect on Therapy. In Geoffrey W. McCaughan, John G. McHutchison, Jean-Michel Pawlotsky (Eds.), Advanced Therapy for Hepatitis C, (pp. 169-176). Chichester, United Kingdom: Wiley-Blackwell Publishing.
  • Pattullo, V., George, J. (2010). Managing the Patient with Chronic Viral Hepatitis Receiving Chemotherapy. In Monica Robotin, Ian Olver, Afaf Girgis (Eds.), When Cancer Crosses Disciplines: A Physicians Handbook, (pp. 813-832). London: Imperial College Press.
  • van der Poorten, D., Milner, K., George, J. (2009). Effect of adipokines on liver disease in females. In Ichiro Shimizu (Eds.), Female Hepatology: Impact of female sex against progression of liver disease, (pp. 191-212). India: Research Signpost.
  • George, J., Talley, N., Segal, I., Weltman, M. (2008). Evaluating abnormal liver tests. In N Talley, I Segal, M Weltman (Eds.), Gastroenterology and Hepatology: a clinical handbook, (pp. 316-326). Australia: Elsevier.
  • Teoh, N., George, J. (2007). Abnormal Liver Function Tests. In N Talley, I Segal, M Weltman (Eds.), Gastroenterology and Hepatology: a clinical handbook. Australia: Elsevier.

Journals

  • Douglas, M., Esmaili, S., George, J. (2014). A new role for IKK-α in Hepatitis C virus induced lipogenesis. Hepatology, 59(5), 2046-2049. [More Information]
  • Beard, M., Ffrench, R., Gowans, E., Helbig, K., Eyre, N., Douglas, M., Grebely, J., Ahlenstiel, G., Locarnini, S., George, J., et al (2014). A Summary of the 20(th) International Symposium on Hepatitis C Virus and Related Viruses. Gastroenterology, 147(1), e1-e4. [More Information]
  • Flynn, J., Sacks-Davis, R., Higgs, P., Aitken, C., Moneer, S., Suppiah, V., Tracy, L., Ffrench, R., Bowden, S., Drummer, H., George, J., et al (2014). Detection of HCV-Specific IFN-gamma Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users. Hepatitis Monthly, 14(1), 1-14. [More Information]
  • Roberts, S., Mitchell, J., Leung, R., Booth, D., Bollipo, S., Ostapowicz, G., Sloss, A., McCaughan, G., Dore, G., Thompson, A., George, J., et al (2014). Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies. Journal of Gastroenterology and Hepatology, 29(1), 179-184. [More Information]
  • Dai, Y., Jiao, H., Teng, G., Wang, W., Zhang, R., Wang, Y., Hebbard, L., George, J., Qiao, L. (2014). Embelin Reduces Colitis-Associated Tumorigenesis through Limiting IL-6/STAT3 Signaling. Molecular Cancer Therapeutics, 13(5), 1206-1216. [More Information]
  • Thomsen, K., Gronbaek, H., Glavind, E., Hebbard, L., Jessen, N., Clouston, A., George, J., Vilstrup, H. (2014). Experimental non-alcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function. American Journal of Physiology: Gastrointestinal and Liver Physiology, 307(3), G295-G301. [More Information]
  • O'Connor, K., Parnell, G., Patrick, E., Ahlenstiel, G., Suppiah, V., van der Poorten, D., Read, S., Leung, R., Douglas, M., Yang, J., Stewart, G., Liddle, C., George, J., Booth, D. (2014). Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent. Genes and Immunity, 15(2), 88-94. [More Information]
  • Eslam, M., Leung, R., Romero-Gomez, M., Mangia, A., Irving, W., Sheridan, D., Spengler, U., Mollison, L., Cheng, W., Bugianesi, E., Douglas, M., Booth, D., George, J., Ahlenstiel, G., et al (2014). IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. Journal of Hepatology, 61(2), 235-241. [More Information]
  • Wilson, G., George, J. (2014). Physical and Chemical Insults Induce Inflammation and Gastrointestinal Cancers. Cancer Letters, 345(2), 190-195. [More Information]
  • Barrera, F., George, J. (2014). Prothrombotic factors and NAFLD: An additional link to cardiovascular risk? Hepatology, 59(1), 16-18. [More Information]
  • Angulo, P., George, J., Day, C., Vanni, E., Russell, L., De la Cruz, A., Liaquat, H., Mezzabotta, L., Lee, E., Bugianesi, E. (2014). Serum Ferritin Levels Lack Diagnostic Accuracy for Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 12(7), 1163-1169. [More Information]
  • Dai, Y., Wilson, G., Huang, B., Peng, M., Teng, G., Zhang, D., Zhang, R., Ebert, M., Chen, J., Wong, B., George, J., Qiao, L., et al (2014). Silencing of Jagged1 inhibits cell growth and invasion in colorectal cancer. Cell Death and Disease, 5, 1-9. [More Information]
  • Grebely, J., Page, K., Sacks-Davis, R., Schim van der Loeff, M., Rice, T., Bruneau, J., Morris, M., Hajarizadeh, B., Amin, J., Cox, A., George, J., et al (2014). The Effects of Female Sex, Viral Genotype, and IL28B Genotype on Spontaneous Clearance of Acute Hepatitis C Virus Infection. Hepatology, 59(1), 109-120. [More Information]
  • Barrera Martinez, F., George, J. (2014). The Role of Diet and Nutritional Intervention for the Management of Patients with NAFLD. Clinics in Liver Disease, 18(1), 91-112. [More Information]
  • Fischer, J., Bohm, S., Muller, T., Witt, H., Sarrazin, C., Susser, S., Migaud, P., Schott, E., Stewart, G., Brodzinski, A., George, J., et al (2013). Association of IFNL3 rs12979860 and rs8099917 with Biochemical Predictors of Interferon Responsiveness in Chronic Hepatitis C Virus Infection. PLoS One, 8(10), 1-11. [More Information]
  • Fahrtash, F., Kariyawasam, V., Gray, T., Byth Wilson, K., George, J., Douglas, M. (2013). Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B. World Journal of Gastroenterology, 19(5), 721-726. [More Information]
  • Suppiah, V., Armstrong, N., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Dore, G., Irving, W., Stewart, G., George, J., Booth, D., Ahlenstiel, G., et al (2013). CCR5-Delta32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. Genes and Immunity, 14(5), 286-290. [More Information]
  • Carulli, L., Maurantonio, M., Hebbard, L., Baldelli, E., Loria, P., George, J. (2013). Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD. Current Pharmaceutical Design, 19(29), 5280-5296. [More Information]
  • Kim, M., Lee, K., Iseli, T., Hoy, A., George, J., Grewal, T., Roufogalis, B. (2013). Compound K modulates fatty acid-induced lipid droplet formation and expression of proteins involved in lipid metabolism in hepatocytes. Liver International, 33(10), 1583-1593. [More Information]
  • Hu, L., George, J., Wang, J. (2013). Current concepts on the role of nitric oxide in portal hypertension. World Journal of Gastroenterology, 19(11), 1707-1717. [More Information]
  • Foster, G., Zeuzem, S., Pianko, S., Sarin, S., Piratvisuth, T., Shah, S., Andreone, P., Sood, A., Chuang, W., Lee, C., George, J., et al (2013). Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin. Journal of Viral Hepatitis, 20(4), e115-e123. [More Information]
  • Petta, S., Rosso, C., Leung, R., Abate, M., Booth, D., Solomone, F., Gambino, R., Rizzetto, M., Caviglia, P., Smedile, A., George, J., et al (2013). Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients with Genotype 1 Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 11(3), 311-317. [More Information]
  • Wilson, G., Hu, Z., Duan, W., Tian, A., Wang, X., McCleod, D., Lam, V., George, J., Qiao, L. (2013). Efficacy of Using Cancer Stem Cell Markers in Isolating and Characterising Liver Cancer Stem Cells. Stem Cells and Development, 22(19), 2655-2664. [More Information]
  • Robotin, M., Patton, Y., George, J. (2013). Getting it right: The impact of a continuing medical education program on hepatitis B knowledge of Australian primary care providers. International Journal of General Medicine, 6(115), 122. [More Information]
  • van der Poorten, D., Samer, C., Ramezani-Moghadam, M., Coulter, S., Kacevska, M., Schrijnders, D., Wu, L., McLeod, D., Bugianesi, E., Komuta, M., Liddle, C., Hebbard, L., George, J., et al (2013). Hepatic Fat Loss in Advanced Nonalcoholic Steatohepatitis: Are Alterations in Serum Adiponectin the Cause? Hepatology, 57(6), 2180-2188. [More Information]
  • Sacks-Davis, R., Atiken, C., Higgs, P., Spelman, T., Pedrana, A., Bowden, S., Bharadwaj, M., Nivarthi, U., Suppiah, V., George, J., et al (2013). High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: A prospective cohort study. PLoS One, 8(11), 1-12. [More Information]
  • Gelinas, J., Fabre, T., Willems, P., Leung, R., George, J., Willems, B., Bruneau, J., Shoukry, N. (2013). IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based test. Immunogenetics, 65(6), 397-403. [More Information]
  • Fischer, J., Bohm, S., George, J., Sarrazin, C., Berg, T. (2013). Impact of cohort size and host factors on combined analysis of interleukin 28B rs12979860 and rs8099917 in hepatitis c virus infection. Hepatology, 57(1), 416-417. [More Information]
  • Eslam, M., Booth, D., George, J., Ahlenstiel, G. (2013). Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection. World Journal of Gastroenterology, 19(41), 7055-7061. [More Information]
  • Booth, D., George, J. (2013). Loss of function of the new interferon IFN-λ4 may confer protection from hepatitis C. Nature Genetics, 45(2), 119-120. [More Information]
  • Barrera Martinez, F., George, J. (2013). Non-alcoholic fatty liver disease: more than just ectopic fat accumulation. Drug Discovery Today: Disease Mechanisms, 10(1-2), e47-e54. [More Information]
  • Hashemi, S., van der Poorten, D., Barrera Martinez, F., Bandara, P., Lux, O., Kench, J., George, J. (2013). Oxidative stress is closely associated with insulin resistance in genotypes 1 and 3 chronic hepatitis C. Hepatology International, 7(2), 516-523. [More Information]
  • Grebely, J., Feld, J., Applegate, T., Matthews, G., Hellard, M., Sherker, A., Petoumenos, K., Zang, G., Shaw, I., Yeung, B., George, J., et al (2013). Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology, 57(6), 2124-2134. [More Information]
  • Sublette, V., Douglas, M., McCaffery, K., George, J., Nicholson Perry, K. (2013). Psychological, lifestyle and social predictors of hepatitis c treatment response: a systematic review. Liver International, 33(6), 894-903. [More Information]
  • Dong, Z., Su, L., Brymora, J., Bird, C., Xie, Q., George, J., Wang, J. (2013). Resistin mediates the hepatic stellate cell phenotype. World Journal of Gastroenterology, 19(28), 4475-4485. [More Information]
  • Angulo, P., Bugianesi, E., Bjornsson, E., Charatcharoenwitthaya, P., Mills, P., Barrera Martinez, F., Haflidadottir, S., Day, C., George, J. (2013). Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology, 145(4), 782-789. [More Information]
  • Mahady, S., George, J. (2013). The Future Liver of the Asia Pacific: Fatter and Firmer from More Fructose and Fortune? Journal of Clinical and Experimental Hepatology, 3(2), 106-113. [More Information]
  • Poustchi, H., Eslami, M., Ostovaneh, M., Modabbernia, A., Saeedian, F., Taslimi, S., George, J., Malekzadeh, R., Zamani, F. (2013). Transient elastography in hepatitis C virus-infected patients with beta-thalassemia for assessment of fibrosis. Hepatology Research, 43(12), 1276-1283. [More Information]
  • Wilson, G., Tian, A., Hebbard, L., Duan, W., George, J., Li, X., Qiao, L. (2013). Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro. Cancer Letters, 341(2), 224-230. [More Information]
  • Vongsuvanh, R., George, J., Qiao, L., van der Poorten, D. (2013). Visceral adiposity in gastrointestinal and hepatic carcinogenesis. Cancer Letters, 330(1), 1-10. [More Information]
  • Kitson, M., Dore, G., George, J., Button, P., McCaughan, G., Crawford, D., Sievert, W., Weltman, M., Cheng, W., Roberts, S. (2013). Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. Journal of Hepatology, 58(3), 467-472. [More Information]
  • Nguyen, V., George, J., van der Poorten, D. (2012). A maxillary mass in a HBV-cirrhotic patient. Liver International, 32(6), 988-988. [More Information]
  • Rahman, W., Huang, P., Belov, L., Chrisp, J., Christopherson, R., Stapelberg, P., Warner, F., George, J., Bowen, D., Strasser, S., Koorey, D., Sharland, A., McCaughan, G., Shackel, N. (2012). Analysis of human liver disease using a cluster of differentiation (CD) antibody microarray. Liver International, 32(10), 1527-1534. [More Information]
  • Fischer, J., Bohm, S., Scholz, M., Muller, T., Witt, H., George, J., Sarrazin, C., Susser, S., Schott, E., Suppiah, V., Booth, D., Stewart, G., et al (2012). Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology, 55(6), 1700-1710. [More Information]
  • Raftopoulos, S., George, J., Bourliere, M., Rossi, E., de Boer, W., Jeffrey, G., Bulsara, M., Speers, D., MacQuillan, G., Ching, H., McLeod, D., et al (2012). Comparison of noninvasive models of fibrosis in chronic hepatitis B. Hepatology International, 6(2), 457-467. [More Information]
  • Robotin, M., Patton, Y., Kansil, M., Penman, A., George, J. (2012). Cost of treating chronic hepatitis B: Comparison of current treatment guidelines. World Journal of Gastroenterology, 18(42), 6106-6113. [More Information]
  • Johnson, N., van Overbeek, D., Chapman, P., Thompson, M., Sachinwalla, T., George, J. (2012). Effect of prolonged exercise and pre-exercise dietary manipulation on hepatic triglycerides in trained men. European Journal of Applied Physiology, 112(5), 1817-1825. [More Information]
  • Keating, S., Hackett, D., George, J., Johnson, N. (2012). Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis. Journal of Hepatology, 57(1), 157-166. [More Information]
  • Johnson, N., Keating, S., George, J. (2012). Exercise and the Liver: Implications for Therapy in Fatty Liver Disorders. Seminars in Liver Disease, 32(1), 65-79. [More Information]
  • Patin, E., Kutalik, Z., Guergnon, J., Bibert, S., Nalpas, B., Jouanguy, E., Munteanu, M., Bousquet, L., Argiro, L., Halfon, P., Suppiah, V., Stewart, G., Booth, D., George, J., et al (2012). Genome-Wide Association Study Identifies Variants Associated With Progression of Liver Fibrosis From HCV Infection. Gastroenterology, 143(5), 1244-1252. [More Information]
  • Gidding, H., Law, M., Amin, J., Ostapowicz, G., Weltman, M., Macdonald, G., Sasadeusz, J., Haber, P., George, J., Dore, G. (2012). Hepatitis C treatment outcomes in Australian clinics. Medical Journal of Australia, 196(10), 633-637. [More Information]
  • Mahady, S., George, J. (2012). Management of nonalcoholic steatohepatitis: an evidence-based approach. Clinics in Liver Disease, 16(3), 631-645. [More Information]
  • Parker, H., Johnson, N., Burdon, C., Cohn, J., O'Connor, H., George, J. (2012). Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis. Journal of Hepatology, 56(4), 944-951. [More Information]
  • Booth, D., Ahlenstiel, G., George, J. (2012). Pharmacogenomics of hepatitis C infections: personalizing therapy. Genome Medicine, 4(12), 1-10. [More Information]
  • Mahady, S., Wong, G., Craig, J., George, J. (2012). Pioglitazone and Vitamin E for Nonalcoholic Steatohepatitis: A Cost Utility Analysis. Hepatology, 56(6), 2172-2179. [More Information]
  • Pianko, S., Zeuzem, S., Chuang, W., Foster, G., Sarin, S., Flisiak, R., Lee, C., Andreone, P., Piratvisuth, T., Shah, S., George, J., et al (2012). Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. Journal of Viral Hepatitis, 19(9), 623-634. [More Information]
  • Poutschi, H., George, J. (2012). Reply. Hepatology, 55(6), 2039-2040. [More Information]
  • Parker, H., Johnson, N., George, J. (2012). Reply to: "The optimal dose of omega-3 supplementation for non-alcoholic fatty liver disease". Journal of Hepatology, 57(2), 469-470. [More Information]
  • Thein, H., Walter, S., Gidding, H., Amin, J., Law, M., George, J., Dore, G. (2012). Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort. Hepatology Research, 42(12), 1175-1186. [More Information]
  • Grebely, J., Hellard, M., Applegate, T., Petoumenos, K., Yeung, B., Feld, J., Rawlinson, W., Lloyd, A., George, J., Kaldor, J., et al (2012). Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection. AIDS, 26(13), 1653-1661. [More Information]
  • Vongsuvanh, R., George, J., McLeod, D., van der Poorten, D. (2012). Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 57(2), 392-398. [More Information]
  • Ahlenstiel, G., Booth, D., George, J. (2012). Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms? Antiviral Therapy, 17(6 Pt B), 1163-1170. [More Information]
  • Hebbard, L., George, J. (2011). Animal models of nonalcoholic fatty liver disease. Nature Reviews. Gastroenterology & Hepatology, 8(1), 35-44. [More Information]
  • Ahlenstiel, G., Booth, D., George, J. (2011). Clinical significance of IL28B gene variation in hepatitis C virus infection. Hot Topics in viral Hepatitis, (20), 17-24. [More Information]
  • Adams, L., George, J., Bugianesi, E., Rossi, E., de Boer, W., van der Poorten, D., Ching, H., Bulsara, M., Jeffrey, G. (2011). Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology, 26(10), 1536-1543. [More Information]
  • Poustchi, H., Farrell, G., Strasser, S., Lee, A., McCaughan, G., George, J. (2011). Feasibility of conducting a randomised control trial for liver cancer screening: Is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology, 54(6), 1998-2004. [More Information]
  • Poustchi, H., George, J., Esmaili, S., Esna-Ashari, F., Ardalan, G., Sepanlou, G., Alavian, S. (2011). Gender differences in healthy ranges for serum alanine aminotransferase levels in adolescence. PLoS One, 6(6), e21178-1-e21178-7. [More Information]
  • Smith, K., Suppiah, V., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Matthews, G., Irving, W., Ahlenstiel, G., Stewart, G., George, J., Booth, D., et al (2011). Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Medicine, 3(8), 57-1-57-13. [More Information]
  • Suppiah, V., Gaudieri, S., Armstrong, N., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Dore, G., Ahlenstiel, G., Stewart, G., George, J., Booth, D., et al (2011). IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study. PLoS Medicine, 8(9), e1001092-1-e1001092-8. [More Information]
  • Liu, Y., Brymora, J., Zhang, H., Smith, B., Ramezani-Moghadam, M., George, J., Wang, J. (2011). Leptin and Acetaldehyde Synergistically Promotes aSMA Expression in Hepatic Stellate Cells by an Interleukin 6-Dependent Mechanism. Alcoholism: Clinical and Experimental Research, 35(5), 921-928. [More Information]
  • Park, G., Wiseman, E., George, J., Katelaris, P., Seow, F., Fung, C., Ngu, M. (2011). Non-invasive Estimation of Liver Fibrosis in Non-alcoholic Fatty Liver Disease Using the (13) C-Caffeine Breath Test. Journal of Gastroenterology and Hepatology, 26(9), 1411-1416. [More Information]
  • Patel, K., Jhaveri, R., George, J., Qiang, G., Kenedi, C., Brown, K., Cates, C., Zekry, A., Tillmann, H., Elliott, L., et al (2011). Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C. Journal of Viral Hepatitis, 18(5), 331-337. [More Information]
  • Pattullo, V., Douglas, M., George, J. (2011). Organelle dysfunction in hepatitis C virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis? Expert Review of Gastroenterology and Hepatology, 5(2), 265-277. [More Information]
  • Gidding, H., Law, M., Amin, J., Macdonald, G., Sasadeusz, J., Jones, T., Strasser, S., George, J., Dore, G. (2011). Predictors of deferral of treatment for hepatitis C infection in Australian clinics. Medical Journal of Australia, 194(8), 398-402. [More Information]
  • Walter, S., Thein, H., Gidding, H., Amin, J., Law, M., George, J., Dore, G. (2011). Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. Journal of Gastroenterology and Hepatology, 26(12), 1757-1764. [More Information]
  • Jacobson, I., McHutchison, J., Dusheiko, G., Di Bisceglie, A., Reddy, K., Bzowej, N., Marcellin, P., Muir, A., Ferenci, P., Flisiak, R., George, J., et al (2011). Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection. New England Journal of Medicine, 364(25), 2405-2416. [More Information]
  • Bhala, N., Angulo, P., van der Poorten, D., Lee, E., Hui, J., Saracco, G., Adams, L., Charatcharoenwitthaya, P., Topping, J., Bugianesi, E., George, J., et al (2011). The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study. Hepatology, 54(4), 1208-1216. [More Information]
  • Mahady, S., Webster, A., Walker, S., Sanyal, A., George, J. (2011). The role of thiazolidinediones in non-alcoholic steatohepatitis - A systematic review and meta analysis. Journal of Hepatology, 55(6), 1383-1390. [More Information]
  • Thein, H., Walter, S., Gidding, H., Amin, J., Law, M., George, J., Dore, G. (2011). Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a population-based cohort study, 1992–2007. Journal of Viral Hepatitis, 18(7), e232-e241. [More Information]
  • Walter, S., Thein, H., Amin, J., Gidding, H., Ward, K., Law, M., George, J., Dore, G. (2011). Trends in mortality after diagnosis of hepatitis B or C infection: 1992–2006. Journal of Hepatology, 54(5), 879-886. [More Information]
  • Johnson, N., George, J. (2010). An Active Part in Treating Liver Disease. Exercise In Medical Conditions: Exercise And Non-Alcoholic Fatty Liver Disease. SportEx Health, 25, 18-20.
  • Milner, K., van der Poorten, D., Trenell, M., Jenkins, A., Xu, A., Smythe, G., Dore, G., Zekry, A., Weltman, M., Fragomeli, V., George, J., et al (2010). Chronic Hepatitis C is Associated with Peripheral rather than Hepatic Insulin Resistance. Gastroenterology, 138(3), 932-941. [More Information]
  • Johnson, N., George, J. (2010). Fitness Versus Fatness: Moving Beyond Weight Loss in Nonalcoholic Fatty Liver Disease. Hepatology, 52(1), 370-381. [More Information]
  • van der Poorten, D., Shahidi, M., Tay, E., Sesha, J., Tran, K., McLeod, D., Milliken, J., Ho, V., Hebbard, L., Douglas, M., George, J. (2010). Hepatitis C Virus Induces the Cannabinoid Receptor 1. PLoS One, 5(9), 1-10. [More Information]
  • Mahady, S., George, J. (2010). How to Treat: Hepatitis C infection. Australian Doctor, , 1-6.
  • Ahlenstiel, G., Booth, D., George, J. (2010). IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. Journal of Gastroenterology and Hepatology, 45(9), 903-910. [More Information]
  • Bhala, N., Usherwood, T., George, J. (2010). Nichtalkoholische Fettlebererkrankung [Non-alcoholic fatty liver]. Praxis, 99(3), 187-189. [More Information]
  • Grebely, J., Petoumenos, K., Hellard, M., Matthews, G., Suppiah, V., Applegate, T., Yeung, B., Marks, P., Rawlinson, W., Lloyd, A., Booth, D., George, J., et al (2010). Potential Role for Interleukin-28B Genotype in Treatment Decision-Making in Recent Hepatitis C Virus Infection. Hepatology, 52(4), 1216-1224. [More Information]
  • Patterson, S., George, J., Strasser, S., Lee, A., Sievert, W., Nicoll, A., Desmond, P., Roberts, S., Locarnini, S., Bowden, S., et al (2010). Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut (English Edition): an international journal of gastroenterology and hepatology, 60(2), 247-254. [More Information]
  • Hebbard, L., George, J. (2010). The chicken or the egg: adipocytes and hepatic insulin resistance. Hepatology, 51(3), 1076-1079. [More Information]
  • Robotin, M., Kansil, M., George, J., Howard, K., Tipper, S., Levy, M., Phung, N., Penman, A. (2010). Using a population-based approach to prevent hepatocellular cancer in New South Wales, Australia: effects on health services utilisation. BMC Health Services Research, 10, 215-224. [More Information]
  • Milner, K., van der Poorten, D., Xu, A., Bugianesi, E., Kench, J., Lam, K., Chisholm, D., George, J. (2009). Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology, 49(6), 1926-1934. [More Information]
  • Smith, B., George, J. (2009). Adipocyte-hepatocyte crosstalk and the pathogenesis of nonalcoholic fatty liver disease. Hepatology, 49(5), 1765-1767. [More Information]
  • Johnson, N., Sachinwalla, T., Walton, D., Smith, K., Armstrong, A., Thompson, M., George, J. (2009). Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology, 50(4), 1105-1112. [More Information]
  • Robotin, M., Kansil, M., Howard, K., George, J., Tipper, S., Dore, G., Levy, M., Penman, A. (2009). Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. Journal of Hepatology, 50(5), 990-998. [More Information]
  • Booth, M., Dobbins, T., Aitken, R., Denney-Wilson, E., Hardy, L., Okely, A., George, J., Sullivan, D., Cowell, C. (2009). Costs of managing conditions associated with obesity among Australian teenagers. Journal of Paediatrics and Child Health, 45(7-8), 448-456. [More Information]
  • Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M., Bassendine, M., Spengler, U., Dore, G., Powell, E., Stewart, G., Booth, D., George, J., et al (2009). IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature Genetics, 41(10), 1100-1104. [More Information]
  • Johnson, N., St George, A., George, J. (2009). Impact of lifestyle modification on patients with chronic liver disease. Hot Topics in viral Hepatitis, 5(14), 17-22.
  • St George, A., Bauman, A., Johnston, A., Farrell, G., Chey, T., George, J. (2009). Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology, 50(1), 68-76. [More Information]
  • Wang, J., Leclercq, I., Brymora, J., Xu, N., Ramezani-Moghadam, M., London, R., Brigstock, D., George, J. (2009). Kupffer Cells Mediate Leptin-Induced Liver Fibrosis. Gastroenterology, 137(2), 713-723. [More Information]
  • Douglas, M., George, J. (2009). Molecular mechanisms of insulin resistance in chronic hepatitis C. World Journal of Gastroenterology, 15(35). [More Information]
  • Bhala, N., Usherwood, T., George, J. (2009). Non-alcoholic fatty liver disease. BMJ: British Medical Journal, 339(b2474), 513-514. [More Information]
  • George, J., Robotin, M. (2009). Overview: Hepatocellular carcinoma - the future starts now. Cancer Forum, 33(2), 83-87.
  • Phung, T., Pera, N., Farrell, G., Leclercq, I., Hou, J., George, J. (2009). Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis. International Journal of Molecular Medicine, 24, 171-180. [More Information]
  • Milner, K., Chisholm, D., George, J. (2009). The many faces of hepatitis C: liver disease and type 2 diabetes. Hepatology, 50(3), 668-670. [More Information]
  • Van Hazel, G., Pavlakis, N., Goldstein, D., Olver, I., Tapner, M., Price, D., Bower, G., Briggs, G., Rossleigh, M., Taylor, D., George, J. (2009). Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy. Journal of Clinical Oncology, 27(25), 4089-4095. [More Information]
  • Poustchi, H., Mohamadkhani, A., Bowden, S., Montazeri, G., Ayres, A., Revill, P., Farrell, G., Locarnini, S., George, J., Malekzadeh, R. (2008). Clinical significance of precore and core promoter mutations in genotype D hepatitis B-related chronic liver disease. Journal of Viral Hepatitis, 15(10), 753-760.
  • van der Poorten, D., George, J. (2008). Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. Clinics in Liver Disease, 12(4), 805-824. [More Information]
  • St George, A., Bauman, A., Johnston, A., Farrell, G., Chey, T., George, J. (2008). Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. Hepatology, (doi:10.1111/j.1440-1746.2008.05694.x), 1-9. [More Information]
  • Cua, I., Hui, J., Kench, J., George, J. (2008). Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology, 48(3), 723-731. [More Information]
  • Poustchi, H., Negro, F., Hui, J., Cua, I., Brandt, L., Kench, J., George, J. (2008). Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. Journal of Hepatology, 48(1), 28-34. [More Information]
  • Cua, I., George, J. (2008). Insulin resistance, adipocytokines and HCV infection: A missing link? Hepatology, 47, 760-761.
  • George, J., Liddle, C. (2008). Nonalcoholic fatty liver disease: Pathogenesis and potential for nuclear receptors as therapeutic targets. Molecular Pharmaceutics, 5(1), 49-59. [More Information]
  • van der Poorten, D., George, J. (2008). Nonalcoholic steatohepatitis is frequently acompanied by metabolic diseases: Reply to the Editor. Hepatology, 48(5), 1729. [More Information]
  • Johnson, N., Walton, D., Sachinwalla, T., Thompson, C., Smith, K., Ruell, P., Stannard, S., George, J. (2008). Noninvasive assessment of hepatic lipid composition: advancing understanding and management of fatty liver disorders. Hepatology, 47, 1513-1523. [More Information]
  • van der Poorten, D., Kenny, D., George, J. (2008). Prevalence of and risk factors for hepatitis C in Aboriginal and non-Aboriginal adolescent offenders. Medical Journal of Australia, 188(10), 610-614. [More Information]
  • Robotin, M., George, J., Supramaniam, R., Sitas, F., Penman, A. (2008). Preventing primary liver cancer: how well are we faring towards a national hepatitis B strategy? Medical Journal of Australia, 188(6), 363-365. [More Information]
  • Johnson, N., Sachinwalla, T., George, J. (2008). Reply: In Vitro Proton Magnetic Resonance Spectroscopy of Liver Tissue Informs In Vivo Hepatic Proton Magnetic Resonance Spectroscopy Studies. Hepatology, 48(3), 1016-1017. [More Information]
  • Wang, J., Brymora, J., George, J. (2008). Roles of adipokines in liver injury and fibrosis. Expert Review of Gastroenterology and Hepatology, 2(1), 47-57.
  • George, J., Denney-Wilson, E., Okely, A., Hardy, L., Aitken, R. (2008). The population distributions, upper normal limits and correlations between liver tests among Australian adolescents. Journal of Paediatrics and Child Health, 44(10), 579-585. [More Information]
  • Booth, M., George, J., Denney-Wilson, E., Okely, A., Hardy, L., Aitken, R., Dobbins, T. (2008). The population prevalence of adverse concentrations and associations with adiposity of liver tests among Australian adolescents. Journal of Paediatrics and Child Health, 44(12), 686-691. [More Information]
  • Yan, K., Guirgis, M., Dinh, T., George, J., Dev, A., Lee, A., Zekry, A. (2008). Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World Journal of Gastroenterology, 14(21), 3416-3420. [More Information]
  • van der Poorten, D., Milner, K., Hui, J., Hodge, A., Trenell, M., Kench, J., London, R., Peduto, A., Chisholm, D., George, J. (2008). Visceral fat: A key mediator of steatohepatitis in metabolic liver disease. Hepatology, 48(2), 449-457. [More Information]
  • van der Poorten, D., Kenny, D., George, J. (2007). A new upper limit for alanine aminotransferase and risk factors for raised alt and hepatitis C in adolescents: a study of 439 male adolescent offenders on community orders. Journal of Gastroenterology and Hepatology, 22(Supplement 3), A344-A344.
  • Angulo, P., George, J., Marchesini, G., Bugianesi, E., Farrell, G., Day, C. (2007). Author's reply: Non-invasive markers of advanced histology in nonalcoholic fatty liver disease. Gastroenterology, 133(4), 1377-1378.
  • van der Poorten, D., George, J. (2007). Current and novel therapies for the treatment of nonalcoholic steatohepatitis. Hepatology International, 1(3), 343-354. [More Information]
  • Cua, I., Hui, J., Bandara, P., Kench, J., Farrell, G., McCaughan, G., George, J. (2007). Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology, 46(1), 66-73. [More Information]
  • van der Poorten, D., Kenny, D., Butler, T., George, J. (2007). Liver disease in adolescents: A cohort study of high-risk individuals. Hepatology, 46(6), 1750-1758. [More Information]
  • Razali, K., Thein, H., Bell, J., Cooper-Stanbury, M., Dolan, K., Dore, G., George, J., Kaldore, J., Karvelas, M., Li, J., Weltman, M., et al (2007). Modelling the hepatitis C virus epidemic in Australia. Drug and Alcohol Dependence, 91(39509), 228-235. [More Information]
  • London, R., George, J. (2007). Pathogenesis of NASH: Animal Models. Clinics in Liver Disease, 11(1), 55-74. [More Information]
  • Cua, I., George, J. (2007). Reply. Hepatology (Baltimore Md.), 46(6), 2051. [More Information]
  • Angulo, P., Hui, J., Marchesini, G., Bugianesi, E., George, J., Farrell, G., Enders, F., Saksena, S., Burt, A., Bida, J., Kench, J., et al (2007). The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 45(4), 846-854. [More Information]
  • George, J. (2006). Angiopoietin-like proteins: Another player in the metabolic field. Journal of Hepatology, 44(4), 832-834. [More Information]
  • Bugianesi, E., Marchesini, G., Gentilcore, E., Cua, I., Vanni, E., Rizzetto, M., George, J. (2006). Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology, 44(6), 1648-1655. [More Information]
  • Salmond, S., George, J., Strasser, S., Batey, R. (2006). Hep573 study of complementary medicine for chronic hepatitis C. Journal Of Clinical Virology, 36(Supplement 2), S134-S135.
  • Chitturi, S., George, J. (2006). Hepatitis C and overweight. Hot Topics in viral Hepatitis, 2, 15-21.
  • Cua, I., George, J. (2006). Interpretation of abnormal liver tests in patients with diabetes. Diabetes Management Journal, 14, 30-31.
  • Cua, I., George, J. (2006). Interpretation of abnormal liver tests in patients with diabetes. Diabetes Management Journal, 14, 30.
  • Cua, I., Hui, J., Bandara, P., Kench, J., McCaughan, G., George, J. (2006). Is insulin resistance and liver injury in chronic hepatitis C associated with virus-specific alteration in the levels of serum adipocytokines? Journal of Gastroenterology and Hepatology, 21, A22-A22.
  • St George, A., Johnston, A., Bauman, A., Iverson, D., Tapsell, L., McCaughan, G., Strasser, S., McGrath, L., Green, J., Farrell, G., George, J. (2006). Lifestyle intervention in early liver disease: metabolic changes at 3 months. Journal of Gastroenterology and Hepatology, 21(Suppl. 4), A315.
  • Cua, I., Kwan, V., Henriquez, M., Kench, J., George, J. (2006). Long term suppressive therapy with pegylated interferon for chronic hepatitis C associated membranoproliferative glomerulonephritis. Gut (English Edition): an international journal of gastroenterology and hepatology, 55(10), 1521-1522. [More Information]
  • Leandro, G., Mangia, A., Hui, J., Fabris, P., Rubbia-Brandt, L., Colloredo, G., Adinolfi, L., Asselah, T., Jonsson, J., Smedile, A., George, J., et al (2006). Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology, 130(6), 1636-1642. [More Information]
  • Wang, J., Batey, R., George, J. (2006). Role of ethanol in the regulation of hepatic stellate cell function. World Journal of Gastroenterology, 12(43), 6926-6932. [More Information]
  • Poustchi, H., George, J., Farrell, G. (2006). The efficacy of a liver cancer screening program on cancer detection and patient survival. Journal of Gastroenterology and Hepatology, 21, A52-A52.
  • Helbig, K., George, J., Beard, M. (2005). A novel I-TAC promoter polymorphic variant is functional in the presence of replicating HCV in vitro. Journal Of Clinical Virology, 32(2), 137-143. [More Information]
  • Bandara, P., George, J., McCaughan, G., Naidoo, D., Lux, O., Salonikas, C., Kench, J., Byth Wilson, K., Farrell, G. (2005). Antioxidant levels in peripheral blood, disease activity and fibrotic stage in chronic hepatitis C. Liver International, 25(3), 518-526. [More Information]
  • Perry, J., Poustchi, H., George, J., Farrell, G., McCaughan, G., Strasser, S. (2005). Current approaches to the diagnosis and management of hepatocellular carcinoma. Clinical and Experimental Medicine, 5(1), 1-13. [More Information]
  • Adams, L., Bulsara, M., Rossi, E., DeBoer, B., Speers, D., George, J., Kench, J., Farrell, G., McCaughan, G., Jeffrey, G. (2005). Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clinical Chemistry (Washington, DC), 51(10), 1867-1873. [More Information]
  • Kumar, U., Farrell, G., Kench, J., George, J. (2005). Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. Journal of Gastroenterology and Hepatology, 20(9), 1395-1400. [More Information]
  • Dela Pena, A., Leclercq, I., Field, J., George, J., Jones, B., Farrell, G. (2005). NF-kappa B activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology, 129(5), 1663-1674. [More Information]
  • Cua, I., George, J. (2005). Non-alcoholic fatty liver disease. British Journal of Hospital Medicine (London), 66(2), 106-111. [More Information]
  • Hui, J., George, J. (2005). Reply: Adiponectin – Tipping the scales from NAFLD to NASH. Gastroenterology, 128(2), 513-513.
  • Hui, J., George, J. (2005). Reply: Reduced plasma adiponectin: central obesity as an underestimated causative risk factor. Hepatology, 41, 401-402. [More Information]
  • Hui, J., Hodge, A., Farrell, G., Kench, J., Kriketos, A., George, J. (2004). Beyond Insulin Resistance In Nash: Tnf-Alpha Or Adiponectin? Hepatology, 40(1), 46-54. [More Information]
  • Coverdale, S., Khan, M., Byth Wilson, K., Lin, R., Weltman, M., George, J., Samarasinghe, D., Liddle, C., Farrell, G., Kench, J., Crewe, E. (2004). Effects Of Interferon Treatment Response On Liver Complications Of Chronic Hepatitis C: 9-Year Follow-Up Study. American Journal of Gastroenterology, 99(4), 636-644.
  • McCaughan, G., George, J. (2004). Fibrosis Progression In Chronic Hepatitis C Virus Infection. Gut (English Edition): an international journal of gastroenterology and hepatology, 53(3), 318-321.
  • Hui, J., Farrell, G., Kench, J., George, J. (2004). High sensitivity C-reactive protein values do not reliably predict the severity of histological change in NAFLD. Hepatology, 39(5), 1458-1459. [More Information]
  • Sud, A., Hui, J., Farrell, G., Bandara, P., Kench, J., Fung, C., Lin, R., Samarasinghe, D., Liddle, C., McCaughan, G., George, J. (2004). Improved Prediction Of Fibrosis In Chronic Hepatitis C Using Measures Of Insulin Resistance In A Probability Index. Hepatology, 39(5), 1239-1247. [More Information]
  • Kwan, V., George, J. (2004). Liver Disease Due To Parenteral And Enteral Nutrition. Clinics in Liver Disease, 8(4), 893-913, ix-x.
  • Chitturi, S., Farrell, G., George, J. (2004). Non-Alcoholic Steatohepatitis In The Asia-Pacific Region: Future Shock? Journal of Gastroenterology and Hepatology, 19(4), 368-374.
  • Zeuzem, S., Diago, M., Gane, E., Reddy, K., Pockros, P., Prati, D., Shiffman, M., Farci, P., Gitlin, N., O'Brien, C., George, J., et al (2004). Peginterferon Alfa-2a (40 Kilodaltons) and Ribavirin in Patients With Chronic Hepatitis C and Normal Aminotransferase Levels. Gastroenterology, 127(6), 1724-1732.
  • Shao, R., Shi, Z., Gotwals, P., Koteliansky, V., George, J., Rockey, D. (2003). Cell and molecular regulation of endothelin-1 production during hepatic wound healing. Molecular Biology of the Cell, 14(6), 2327-2341.
  • Coverdale, S., Samarasinghe, D., Lin, R., Kench, J., Byth Wilson, K., Khan, M., Crewe, E., Liddle, C., George, J., Farrell, G. (2003). Changes in Antipyrine Clearance and Platelet Count, but Not Conventional Liver Tests, Correlate With Fibrotic Change in Chronic Hepatitis C: Value for Predicting Fibrotic Progression. American Journal of Gastroenterology, 98(6), 1384-1390.
  • Kumar, D., Wallington-Beddoe, C., George, J., Lin, R., Samarasinghe, D., Liddle, C., Farrell, G. (2003). Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hapatitis c in a clinic setting. Medical Journal of Australia, 178(6), 267-271.
  • Hui, J., Sud, A., Farrell, G., Bandara, P., Byth Wilson, K., Kench, J., McCaughan, G., George, J. (2003). Insulin resistance is associated with chronic Hepatitis C and virus infection fibrosis progression. Gastroenterology, 125(6), 1695-1704.
  • Chitturi, S., George, J. (2003). Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Current Gastroenterology, 5(1), 18-25.
  • George, J. (2003). Invited Book Review – Hepatitis C: An Australian perspective. Eds. N Crofts, G Dore and S Locarnini. Internal Medicine Journal, 33(1), 64-64.
  • George, J., Pera, N., Phung, T., Leclercq, I., Hou, J., Farrell, G. (2003). Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. Journal of Hepatology, 39(5), 756-764.
  • Hui, J., Kench, J., Chitturi, S., Sud, A., Farrell, G., Blyth, K., Hall, P., Khan, M., George, J. (2003). Long term outcomes of cirrhosis in nonalcoholic steatohepatitis compares with hepatitis c. Hepatology, 38(2), 420-427.
  • Perry, J., Strasser, S., George, J., Farrell, G., McCaughan, G. (2003). Pharmacotherapy of hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 4(12), 2175-2185.
  • Chitturi, S., Farrell, G., George, J. (2003). Reply: Iron and HFE mutations in nonalcoholic steatohepatitis: Innocent bystanders or accessories to the crime? Gastroenterology, 125(2), 616-616.
  • Lee, D., Chitturi, S., Kench, J., George, J., Fuller, S., Bradstock, K., Lin, R., Wong, K., Young, N. (2003). Transjugular liver biopsy effecting changes in clinical management. Journal of Medical Imaging and Radiation Oncology, 47(2), 117-120. [More Information]
  • Hui, J., George, J., Liddle, C., Lin, R., Samarasinghe, D., Crewe, E., Farrell, G. (2002). Changes in Serum Albumin During Treatment of Chronic Hepatitis B With Lamivudine: Effects of Response and Emergence of Drug Resistance. American Journal of Gastroenterology, 97(4), 1003-1009.
  • Teoh, N., George, J. (2002). Evaluating patients who have abnormal liver tests. Medicine Today, 3(10), 58-67.
  • Chitturi, S., George, J., Ranjitkumar, S., Kench, J., Benson, W. (2002). Exchange Transfusion for Severe Intrahepatic Cholestasis Associated With Sickle Cell Disease. Journal of Clinical Gastroenterology, 35(4), 362-363.
  • Alonso, C., George, J., Pesce, C., Bissell, D., Kornblihtt, A. (2002). Fibronectin transcription in liver cells: promoter occupation and function in sinusoidal endothelial cells and hepatocytes. Biochemical and Biophysical Research Communications, 295(5), 1077-1084.
  • Hui, J., Kench, J., Farrell, G., Lin, R., Samarasinghe, D., Liddle, C., Byth, K., George, J. (2002). Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. Journal of Gastroenterology and Hepatology, 17(8), 873-881.
  • Chitturi, S., Le, V., Kench, J., Loh, C., George, J. (2002). Gliclazide-Induced Acute Hepatitis with Hypersensitivity Features. Digestive diseases and sciences, 47(5), 1107-1110.
  • Hui, J., Farrell, G., Lin, R., Samarasinghe, D., Liddle, C., George, J., Kench, J., Byth, K. (2002). Hepatic Steatosis in Chronic Hepatitis C Infection. Journal of Gastroenterology and Hepatology, 17(8), 873-881.
  • Kumar, S., Farrell, G., Fung, C., George, J. (2002). Hepatitis C Virus Genotype 3 is Cytopathic to Hepatocytes: Reversal of Hepatic Steatosis after Sustained Therapeutic Response. Hepatology, 36(5), 1266-1272.
  • Chitturi, S., George, J. (2002). Hepatotoxicity of Commonly Used Drugs: nonsteroidal Anti-Inflammatory Drugs, Antihypertensives, Antidiabetic Agents, Anticonvulsants, Lipid-Lowering Agents, Psychotropic Drugs. Seminars in Liver Disease, 22(2), 169-183.
  • Chitturi, S., Weltman, M., Farrell, G., McDonald, D., Liddle, C., Samarasinghe, D., Lin, R., Abeygunasekera, S., George, J. (2002). HFE Mutations, Hepatic Iron, and Fibrosis: Ethnic-Specification Association of NASH with C282Y but not with Fibrotic Severity. Hepatology, 36(1), 142-149.
  • Chitturi, S., Abeygunasekera, S., Farrell, G., Holmes-Walker, J., Hui, J., Fung, C., Karim, R., Lin, R., Samarasinghe, D., Liddle, C., Weltman, M., George, J. (2002). NASH and Insulin Resistance: Insulin Hypersecretion and Specific Association with the Insulin Resistance Syndrome. Hepatology, 35(2), 373-379.
  • Chitturi, S., Farrell, G., Frost, L., Kriketos, A., Lin, R., Liddle, C., Samarasinghe, D., George, J. (2002). Serum Leptin in NASH Correlates with Hepatic Steatosis but not Fibrosis: A Manifestation of Lipotoxicity? Hepatology, 36(2), 403-409.
  • Wong, V., Fu, A., George, J., Cheung, N. (2002). Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clinical Endocrinology, 56(6), 793-798.
  • Chitturi, S., Hui, J., Salisbury, E., Mitchell, D., George, J. (2001). Abdominal pain in an intrauterine contraceptive devise user. Postgraduate Medical Journal, 77, 602-610.
  • Chitturi, S., Abeygunasekera, S., Fung, C., Samarasinghe, D., Lin, R., McDonald, D., Weltman, M., Farrell, G., George, J. (2001). Haemochromatosis gene mutations, hepatic iron content and nonalcoholic steatohepatitis. Hepatology, 19, 1768-1778.
  • George, J., Hui, J., Farrell, G., Lin, R., Samarasinghe, D., Kench, J. (2001). Predictors for steatosis and fibrosis in chronic hepatitis C. Journal of Hepatology, 34, 153-153.
  • Farrell, G., Liddle, C., Samarasinghe, D., Lin, R., George, J., Chitturi, S., Frost, L. (2001). Serum Leptin: An independent predictor of hepatic steatosis but not fibrotic severity in nonalcoholic steatohepatitis. Hepatology, 34, 752-752.
  • Pera, N., Phung, H., Leclercq, I., Farrell, G., George, J. (2001). This role of oxidative stress in the evolution of hepatic fibrogenesis in a rodent model of nonalcoholic steatohepatitis. Hepatology, 34, 1132-1132.
  • Bissell,, D., Roulot, D., George, J. (2001). Transforming growth factor B and the liver. Hepatology, 34(5), 859-867.
  • Phung, T., Farrell, G., Robertson, G., George, J. (2001). Vitamin E but not glutathione precursors ameliorates hepatic fibrosis in experimental NASH. Journal of Gastroenterology and Hepatology, 16.
  • Phung, T., Farrell, G., Robertson, G., George, J. (2001). Vitamin E but not glutathione precursors inhibits hepatic fibrosis in experimental NASH exhibiting oxidative stress and mitochondrial abnormalities. Hepatology, 34, 756-756.

Conferences

  • Farrell, G., Phung, T., Ip, E., Dela Pena, A., Robertson, G., Pera, N., George, J., Leclercq, I. (2002). Sources of oxidant stress in fatty liver disorders. Interactive mechanisms, and relevance to fibrosing steatohepatitis. AASLD Single Topic Conference NASH – Nonalcoholic Steatohepatitis.
  • Phung, T., Farrell, G., Robertson, G., George, J. (2001). Antioxidant therapy with vitamin E ameliorates hepatic fibrosis in MCDD-associated NASH. Asia Pacific Digestive Week 2001, : World Scientific Publishing.
  • Leclercq, I., George, J., Farrell, G., Robertson, G., Field, J. (2001). Leptin is an essential mediator of hepatic fibrogenesis and liver regeneration in chronic CCl4-induced liver injury. Asia Pacific Digestive Week 2001, : World Scientific Publishing.
  • Pera, N., Phung, H., Leclercq, I., Farrell, G., George, J. (2001). Oxidative stress and the evolution of hepatic fibrogenesis in a rodent model of nonalcoholic steatohepatitis. Asia Pacific Digestive Week 2001, : World Scientific Publishing.
  • Coverdale, S., Samarasinghe, D., Lin, R., Liddle, C., George, J., Farrell, G., Kench, J., Byth, K., Khan, M., Crewe, E. (2001). Prediction of histological progression in chronic hepatitis C. Asia Pacific Digestive Week 2001, : World Scientific Publishing.
  • Pera, N., Phung, H., Leclercq, I., Farrell, G., George, J. (2001). The role of oxidative stress in the evolution of hepatic fibrogenesis in a rodent model of nonalcoholic steatohepatitis. The American Association for the Study of Liver Diseases 52nd Annual Meeting, : World Scientific Publishing.

Magazine / Newspaper Articles

  • Singal, D., George, J. (2002). Chronic hepatitis C. Australian Doctor.

2014

  • Douglas, M., Esmaili, S., George, J. (2014). A new role for IKK-α in Hepatitis C virus induced lipogenesis. Hepatology, 59(5), 2046-2049. [More Information]
  • Beard, M., Ffrench, R., Gowans, E., Helbig, K., Eyre, N., Douglas, M., Grebely, J., Ahlenstiel, G., Locarnini, S., George, J., et al (2014). A Summary of the 20(th) International Symposium on Hepatitis C Virus and Related Viruses. Gastroenterology, 147(1), e1-e4. [More Information]
  • Flynn, J., Sacks-Davis, R., Higgs, P., Aitken, C., Moneer, S., Suppiah, V., Tracy, L., Ffrench, R., Bowden, S., Drummer, H., George, J., et al (2014). Detection of HCV-Specific IFN-gamma Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users. Hepatitis Monthly, 14(1), 1-14. [More Information]
  • Roberts, S., Mitchell, J., Leung, R., Booth, D., Bollipo, S., Ostapowicz, G., Sloss, A., McCaughan, G., Dore, G., Thompson, A., George, J., et al (2014). Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies. Journal of Gastroenterology and Hepatology, 29(1), 179-184. [More Information]
  • Dai, Y., Jiao, H., Teng, G., Wang, W., Zhang, R., Wang, Y., Hebbard, L., George, J., Qiao, L. (2014). Embelin Reduces Colitis-Associated Tumorigenesis through Limiting IL-6/STAT3 Signaling. Molecular Cancer Therapeutics, 13(5), 1206-1216. [More Information]
  • Thomsen, K., Gronbaek, H., Glavind, E., Hebbard, L., Jessen, N., Clouston, A., George, J., Vilstrup, H. (2014). Experimental non-alcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function. American Journal of Physiology: Gastrointestinal and Liver Physiology, 307(3), G295-G301. [More Information]
  • O'Connor, K., Parnell, G., Patrick, E., Ahlenstiel, G., Suppiah, V., van der Poorten, D., Read, S., Leung, R., Douglas, M., Yang, J., Stewart, G., Liddle, C., George, J., Booth, D. (2014). Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent. Genes and Immunity, 15(2), 88-94. [More Information]
  • Eslam, M., Leung, R., Romero-Gomez, M., Mangia, A., Irving, W., Sheridan, D., Spengler, U., Mollison, L., Cheng, W., Bugianesi, E., Douglas, M., Booth, D., George, J., Ahlenstiel, G., et al (2014). IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. Journal of Hepatology, 61(2), 235-241. [More Information]
  • Wilson, G., George, J. (2014). Physical and Chemical Insults Induce Inflammation and Gastrointestinal Cancers. Cancer Letters, 345(2), 190-195. [More Information]
  • Barrera, F., George, J. (2014). Prothrombotic factors and NAFLD: An additional link to cardiovascular risk? Hepatology, 59(1), 16-18. [More Information]
  • Angulo, P., George, J., Day, C., Vanni, E., Russell, L., De la Cruz, A., Liaquat, H., Mezzabotta, L., Lee, E., Bugianesi, E. (2014). Serum Ferritin Levels Lack Diagnostic Accuracy for Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 12(7), 1163-1169. [More Information]
  • Dai, Y., Wilson, G., Huang, B., Peng, M., Teng, G., Zhang, D., Zhang, R., Ebert, M., Chen, J., Wong, B., George, J., Qiao, L., et al (2014). Silencing of Jagged1 inhibits cell growth and invasion in colorectal cancer. Cell Death and Disease, 5, 1-9. [More Information]
  • Grebely, J., Page, K., Sacks-Davis, R., Schim van der Loeff, M., Rice, T., Bruneau, J., Morris, M., Hajarizadeh, B., Amin, J., Cox, A., George, J., et al (2014). The Effects of Female Sex, Viral Genotype, and IL28B Genotype on Spontaneous Clearance of Acute Hepatitis C Virus Infection. Hepatology, 59(1), 109-120. [More Information]
  • Barrera Martinez, F., George, J. (2014). The Role of Diet and Nutritional Intervention for the Management of Patients with NAFLD. Clinics in Liver Disease, 18(1), 91-112. [More Information]

2013

  • Fischer, J., Bohm, S., Muller, T., Witt, H., Sarrazin, C., Susser, S., Migaud, P., Schott, E., Stewart, G., Brodzinski, A., George, J., et al (2013). Association of IFNL3 rs12979860 and rs8099917 with Biochemical Predictors of Interferon Responsiveness in Chronic Hepatitis C Virus Infection. PLoS One, 8(10), 1-11. [More Information]
  • Fahrtash, F., Kariyawasam, V., Gray, T., Byth Wilson, K., George, J., Douglas, M. (2013). Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B. World Journal of Gastroenterology, 19(5), 721-726. [More Information]
  • Suppiah, V., Armstrong, N., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Dore, G., Irving, W., Stewart, G., George, J., Booth, D., Ahlenstiel, G., et al (2013). CCR5-Delta32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. Genes and Immunity, 14(5), 286-290. [More Information]
  • Carulli, L., Maurantonio, M., Hebbard, L., Baldelli, E., Loria, P., George, J. (2013). Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD. Current Pharmaceutical Design, 19(29), 5280-5296. [More Information]
  • Kim, M., Lee, K., Iseli, T., Hoy, A., George, J., Grewal, T., Roufogalis, B. (2013). Compound K modulates fatty acid-induced lipid droplet formation and expression of proteins involved in lipid metabolism in hepatocytes. Liver International, 33(10), 1583-1593. [More Information]
  • Hu, L., George, J., Wang, J. (2013). Current concepts on the role of nitric oxide in portal hypertension. World Journal of Gastroenterology, 19(11), 1707-1717. [More Information]
  • Foster, G., Zeuzem, S., Pianko, S., Sarin, S., Piratvisuth, T., Shah, S., Andreone, P., Sood, A., Chuang, W., Lee, C., George, J., et al (2013). Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin. Journal of Viral Hepatitis, 20(4), e115-e123. [More Information]
  • Petta, S., Rosso, C., Leung, R., Abate, M., Booth, D., Solomone, F., Gambino, R., Rizzetto, M., Caviglia, P., Smedile, A., George, J., et al (2013). Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients with Genotype 1 Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 11(3), 311-317. [More Information]
  • Wilson, G., Hu, Z., Duan, W., Tian, A., Wang, X., McCleod, D., Lam, V., George, J., Qiao, L. (2013). Efficacy of Using Cancer Stem Cell Markers in Isolating and Characterising Liver Cancer Stem Cells. Stem Cells and Development, 22(19), 2655-2664. [More Information]
  • Robotin, M., Patton, Y., George, J. (2013). Getting it right: The impact of a continuing medical education program on hepatitis B knowledge of Australian primary care providers. International Journal of General Medicine, 6(115), 122. [More Information]
  • van der Poorten, D., Samer, C., Ramezani-Moghadam, M., Coulter, S., Kacevska, M., Schrijnders, D., Wu, L., McLeod, D., Bugianesi, E., Komuta, M., Liddle, C., Hebbard, L., George, J., et al (2013). Hepatic Fat Loss in Advanced Nonalcoholic Steatohepatitis: Are Alterations in Serum Adiponectin the Cause? Hepatology, 57(6), 2180-2188. [More Information]
  • Sacks-Davis, R., Atiken, C., Higgs, P., Spelman, T., Pedrana, A., Bowden, S., Bharadwaj, M., Nivarthi, U., Suppiah, V., George, J., et al (2013). High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: A prospective cohort study. PLoS One, 8(11), 1-12. [More Information]
  • Gelinas, J., Fabre, T., Willems, P., Leung, R., George, J., Willems, B., Bruneau, J., Shoukry, N. (2013). IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based test. Immunogenetics, 65(6), 397-403. [More Information]
  • Fischer, J., Bohm, S., George, J., Sarrazin, C., Berg, T. (2013). Impact of cohort size and host factors on combined analysis of interleukin 28B rs12979860 and rs8099917 in hepatitis c virus infection. Hepatology, 57(1), 416-417. [More Information]
  • Eslam, M., Booth, D., George, J., Ahlenstiel, G. (2013). Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection. World Journal of Gastroenterology, 19(41), 7055-7061. [More Information]
  • Booth, D., George, J. (2013). Loss of function of the new interferon IFN-λ4 may confer protection from hepatitis C. Nature Genetics, 45(2), 119-120. [More Information]
  • Barrera Martinez, F., George, J. (2013). Non-alcoholic fatty liver disease: more than just ectopic fat accumulation. Drug Discovery Today: Disease Mechanisms, 10(1-2), e47-e54. [More Information]
  • Hashemi, S., van der Poorten, D., Barrera Martinez, F., Bandara, P., Lux, O., Kench, J., George, J. (2013). Oxidative stress is closely associated with insulin resistance in genotypes 1 and 3 chronic hepatitis C. Hepatology International, 7(2), 516-523. [More Information]
  • Grebely, J., Feld, J., Applegate, T., Matthews, G., Hellard, M., Sherker, A., Petoumenos, K., Zang, G., Shaw, I., Yeung, B., George, J., et al (2013). Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology, 57(6), 2124-2134. [More Information]
  • Sublette, V., Douglas, M., McCaffery, K., George, J., Nicholson Perry, K. (2013). Psychological, lifestyle and social predictors of hepatitis c treatment response: a systematic review. Liver International, 33(6), 894-903. [More Information]
  • Dong, Z., Su, L., Brymora, J., Bird, C., Xie, Q., George, J., Wang, J. (2013). Resistin mediates the hepatic stellate cell phenotype. World Journal of Gastroenterology, 19(28), 4475-4485. [More Information]
  • Angulo, P., Bugianesi, E., Bjornsson, E., Charatcharoenwitthaya, P., Mills, P., Barrera Martinez, F., Haflidadottir, S., Day, C., George, J. (2013). Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology, 145(4), 782-789. [More Information]
  • Mahady, S., George, J. (2013). The Future Liver of the Asia Pacific: Fatter and Firmer from More Fructose and Fortune? Journal of Clinical and Experimental Hepatology, 3(2), 106-113. [More Information]
  • Poustchi, H., Eslami, M., Ostovaneh, M., Modabbernia, A., Saeedian, F., Taslimi, S., George, J., Malekzadeh, R., Zamani, F. (2013). Transient elastography in hepatitis C virus-infected patients with beta-thalassemia for assessment of fibrosis. Hepatology Research, 43(12), 1276-1283. [More Information]
  • Wilson, G., Tian, A., Hebbard, L., Duan, W., George, J., Li, X., Qiao, L. (2013). Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro. Cancer Letters, 341(2), 224-230. [More Information]
  • Vongsuvanh, R., George, J., Qiao, L., van der Poorten, D. (2013). Visceral adiposity in gastrointestinal and hepatic carcinogenesis. Cancer Letters, 330(1), 1-10. [More Information]
  • Kitson, M., Dore, G., George, J., Button, P., McCaughan, G., Crawford, D., Sievert, W., Weltman, M., Cheng, W., Roberts, S. (2013). Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. Journal of Hepatology, 58(3), 467-472. [More Information]

2012

  • Nguyen, V., George, J., van der Poorten, D. (2012). A maxillary mass in a HBV-cirrhotic patient. Liver International, 32(6), 988-988. [More Information]
  • Rahman, W., Huang, P., Belov, L., Chrisp, J., Christopherson, R., Stapelberg, P., Warner, F., George, J., Bowen, D., Strasser, S., Koorey, D., Sharland, A., McCaughan, G., Shackel, N. (2012). Analysis of human liver disease using a cluster of differentiation (CD) antibody microarray. Liver International, 32(10), 1527-1534. [More Information]
  • Walker, S., George, J., Hebbard, L. (2012). Animal Models of Hepatocellular Carcinoma. In Liang Qiao, Yumin Li, Xiang Yan and Jacob George (Eds.), Molecular Aspects of Hepatocellular Carcinoma, (pp. 116-128). Sharjah: Bentham Science Publishers Ltd.
  • Fischer, J., Bohm, S., Scholz, M., Muller, T., Witt, H., George, J., Sarrazin, C., Susser, S., Schott, E., Suppiah, V., Booth, D., Stewart, G., et al (2012). Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology, 55(6), 1700-1710. [More Information]
  • Raftopoulos, S., George, J., Bourliere, M., Rossi, E., de Boer, W., Jeffrey, G., Bulsara, M., Speers, D., MacQuillan, G., Ching, H., McLeod, D., et al (2012). Comparison of noninvasive models of fibrosis in chronic hepatitis B. Hepatology International, 6(2), 457-467. [More Information]
  • Robotin, M., Patton, Y., Kansil, M., Penman, A., George, J. (2012). Cost of treating chronic hepatitis B: Comparison of current treatment guidelines. World Journal of Gastroenterology, 18(42), 6106-6113. [More Information]
  • Johnson, N., van Overbeek, D., Chapman, P., Thompson, M., Sachinwalla, T., George, J. (2012). Effect of prolonged exercise and pre-exercise dietary manipulation on hepatic triglycerides in trained men. European Journal of Applied Physiology, 112(5), 1817-1825. [More Information]
  • Keating, S., Hackett, D., George, J., Johnson, N. (2012). Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis. Journal of Hepatology, 57(1), 157-166. [More Information]
  • Johnson, N., Keating, S., George, J. (2012). Exercise and the Liver: Implications for Therapy in Fatty Liver Disorders. Seminars in Liver Disease, 32(1), 65-79. [More Information]
  • Patin, E., Kutalik, Z., Guergnon, J., Bibert, S., Nalpas, B., Jouanguy, E., Munteanu, M., Bousquet, L., Argiro, L., Halfon, P., Suppiah, V., Stewart, G., Booth, D., George, J., et al (2012). Genome-Wide Association Study Identifies Variants Associated With Progression of Liver Fibrosis From HCV Infection. Gastroenterology, 143(5), 1244-1252. [More Information]
  • Gidding, H., Law, M., Amin, J., Ostapowicz, G., Weltman, M., Macdonald, G., Sasadeusz, J., Haber, P., George, J., Dore, G. (2012). Hepatitis C treatment outcomes in Australian clinics. Medical Journal of Australia, 196(10), 633-637. [More Information]
  • Mahady, S., George, J. (2012). Management of nonalcoholic steatohepatitis: an evidence-based approach. Clinics in Liver Disease, 16(3), 631-645. [More Information]
  • Qiao, L., Li, Y., Yan, X., George, J. (2012). Molecular Aspects of Hepatocellular Carcinoma. Sharjah: Bentham Science Publishers Ltd.
  • Parker, H., Johnson, N., Burdon, C., Cohn, J., O'Connor, H., George, J. (2012). Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis. Journal of Hepatology, 56(4), 944-951. [More Information]
  • Booth, D., Ahlenstiel, G., George, J. (2012). Pharmacogenomics of hepatitis C infections: personalizing therapy. Genome Medicine, 4(12), 1-10. [More Information]
  • Mahady, S., Wong, G., Craig, J., George, J. (2012). Pioglitazone and Vitamin E for Nonalcoholic Steatohepatitis: A Cost Utility Analysis. Hepatology, 56(6), 2172-2179. [More Information]
  • Pianko, S., Zeuzem, S., Chuang, W., Foster, G., Sarin, S., Flisiak, R., Lee, C., Andreone, P., Piratvisuth, T., Shah, S., George, J., et al (2012). Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. Journal of Viral Hepatitis, 19(9), 623-634. [More Information]
  • Poutschi, H., George, J. (2012). Reply. Hepatology, 55(6), 2039-2040. [More Information]
  • Parker, H., Johnson, N., George, J. (2012). Reply to: "The optimal dose of omega-3 supplementation for non-alcoholic fatty liver disease". Journal of Hepatology, 57(2), 469-470. [More Information]
  • Thein, H., Walter, S., Gidding, H., Amin, J., Law, M., George, J., Dore, G. (2012). Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort. Hepatology Research, 42(12), 1175-1186. [More Information]
  • Pattullo, V., George, J. (2012). The Problem of Insulin Resistance and its Effect on Therapy. In Geoffrey W. McCaughan, John G. McHutchison, Jean-Michel Pawlotsky (Eds.), Advanced Therapy for Hepatitis C, (pp. 169-176). Chichester, United Kingdom: Wiley-Blackwell Publishing.
  • Grebely, J., Hellard, M., Applegate, T., Petoumenos, K., Yeung, B., Feld, J., Rawlinson, W., Lloyd, A., George, J., Kaldor, J., et al (2012). Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection. AIDS, 26(13), 1653-1661. [More Information]
  • Vongsuvanh, R., George, J., McLeod, D., van der Poorten, D. (2012). Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 57(2), 392-398. [More Information]
  • Ahlenstiel, G., Booth, D., George, J. (2012). Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms? Antiviral Therapy, 17(6 Pt B), 1163-1170. [More Information]

2011

  • Hebbard, L., George, J. (2011). Animal models of nonalcoholic fatty liver disease. Nature Reviews. Gastroenterology & Hepatology, 8(1), 35-44. [More Information]
  • Ahlenstiel, G., Booth, D., George, J. (2011). Clinical significance of IL28B gene variation in hepatitis C virus infection. Hot Topics in viral Hepatitis, (20), 17-24. [More Information]
  • Adams, L., George, J., Bugianesi, E., Rossi, E., de Boer, W., van der Poorten, D., Ching, H., Bulsara, M., Jeffrey, G. (2011). Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology, 26(10), 1536-1543. [More Information]
  • Poustchi, H., Farrell, G., Strasser, S., Lee, A., McCaughan, G., George, J. (2011). Feasibility of conducting a randomised control trial for liver cancer screening: Is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology, 54(6), 1998-2004. [More Information]
  • Poustchi, H., George, J., Esmaili, S., Esna-Ashari, F., Ardalan, G., Sepanlou, G., Alavian, S. (2011). Gender differences in healthy ranges for serum alanine aminotransferase levels in adolescence. PLoS One, 6(6), e21178-1-e21178-7. [More Information]
  • Smith, K., Suppiah, V., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Matthews, G., Irving, W., Ahlenstiel, G., Stewart, G., George, J., Booth, D., et al (2011). Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Medicine, 3(8), 57-1-57-13. [More Information]
  • Suppiah, V., Gaudieri, S., Armstrong, N., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Dore, G., Ahlenstiel, G., Stewart, G., George, J., Booth, D., et al (2011). IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study. PLoS Medicine, 8(9), e1001092-1-e1001092-8. [More Information]
  • Liu, Y., Brymora, J., Zhang, H., Smith, B., Ramezani-Moghadam, M., George, J., Wang, J. (2011). Leptin and Acetaldehyde Synergistically Promotes aSMA Expression in Hepatic Stellate Cells by an Interleukin 6-Dependent Mechanism. Alcoholism: Clinical and Experimental Research, 35(5), 921-928. [More Information]
  • Park, G., Wiseman, E., George, J., Katelaris, P., Seow, F., Fung, C., Ngu, M. (2011). Non-invasive Estimation of Liver Fibrosis in Non-alcoholic Fatty Liver Disease Using the (13) C-Caffeine Breath Test. Journal of Gastroenterology and Hepatology, 26(9), 1411-1416. [More Information]
  • Patel, K., Jhaveri, R., George, J., Qiang, G., Kenedi, C., Brown, K., Cates, C., Zekry, A., Tillmann, H., Elliott, L., et al (2011). Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C. Journal of Viral Hepatitis, 18(5), 331-337. [More Information]
  • Pattullo, V., Douglas, M., George, J. (2011). Organelle dysfunction in hepatitis C virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis? Expert Review of Gastroenterology and Hepatology, 5(2), 265-277. [More Information]
  • Gidding, H., Law, M., Amin, J., Macdonald, G., Sasadeusz, J., Jones, T., Strasser, S., George, J., Dore, G. (2011). Predictors of deferral of treatment for hepatitis C infection in Australian clinics. Medical Journal of Australia, 194(8), 398-402. [More Information]
  • Walter, S., Thein, H., Gidding, H., Amin, J., Law, M., George, J., Dore, G. (2011). Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. Journal of Gastroenterology and Hepatology, 26(12), 1757-1764. [More Information]
  • Jacobson, I., McHutchison, J., Dusheiko, G., Di Bisceglie, A., Reddy, K., Bzowej, N., Marcellin, P., Muir, A., Ferenci, P., Flisiak, R., George, J., et al (2011). Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection. New England Journal of Medicine, 364(25), 2405-2416. [More Information]
  • Bhala, N., Angulo, P., van der Poorten, D., Lee, E., Hui, J., Saracco, G., Adams, L., Charatcharoenwitthaya, P., Topping, J., Bugianesi, E., George, J., et al (2011). The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study. Hepatology, 54(4), 1208-1216. [More Information]
  • Mahady, S., Webster, A., Walker, S., Sanyal, A., George, J. (2011). The role of thiazolidinediones in non-alcoholic steatohepatitis - A systematic review and meta analysis. Journal of Hepatology, 55(6), 1383-1390. [More Information]
  • Thein, H., Walter, S., Gidding, H., Amin, J., Law, M., George, J., Dore, G. (2011). Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a population-based cohort study, 1992–2007. Journal of Viral Hepatitis, 18(7), e232-e241. [More Information]
  • Walter, S., Thein, H., Amin, J., Gidding, H., Ward, K., Law, M., George, J., Dore, G. (2011). Trends in mortality after diagnosis of hepatitis B or C infection: 1992–2006. Journal of Hepatology, 54(5), 879-886. [More Information]

2010

  • Johnson, N., George, J. (2010). An Active Part in Treating Liver Disease. Exercise In Medical Conditions: Exercise And Non-Alcoholic Fatty Liver Disease. SportEx Health, 25, 18-20.
  • Milner, K., van der Poorten, D., Trenell, M., Jenkins, A., Xu, A., Smythe, G., Dore, G., Zekry, A., Weltman, M., Fragomeli, V., George, J., et al (2010). Chronic Hepatitis C is Associated with Peripheral rather than Hepatic Insulin Resistance. Gastroenterology, 138(3), 932-941. [More Information]
  • Johnson, N., George, J. (2010). Fitness Versus Fatness: Moving Beyond Weight Loss in Nonalcoholic Fatty Liver Disease. Hepatology, 52(1), 370-381. [More Information]
  • van der Poorten, D., Shahidi, M., Tay, E., Sesha, J., Tran, K., McLeod, D., Milliken, J., Ho, V., Hebbard, L., Douglas, M., George, J. (2010). Hepatitis C Virus Induces the Cannabinoid Receptor 1. PLoS One, 5(9), 1-10. [More Information]
  • Mahady, S., George, J. (2010). How to Treat: Hepatitis C infection. Australian Doctor, , 1-6.
  • Ahlenstiel, G., Booth, D., George, J. (2010). IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. Journal of Gastroenterology and Hepatology, 45(9), 903-910. [More Information]
  • Pattullo, V., George, J. (2010). Managing the Patient with Chronic Viral Hepatitis Receiving Chemotherapy. In Monica Robotin, Ian Olver, Afaf Girgis (Eds.), When Cancer Crosses Disciplines: A Physicians Handbook, (pp. 813-832). London: Imperial College Press.
  • Bhala, N., Usherwood, T., George, J. (2010). Nichtalkoholische Fettlebererkrankung [Non-alcoholic fatty liver]. Praxis, 99(3), 187-189. [More Information]
  • Grebely, J., Petoumenos, K., Hellard, M., Matthews, G., Suppiah, V., Applegate, T., Yeung, B., Marks, P., Rawlinson, W., Lloyd, A., Booth, D., George, J., et al (2010). Potential Role for Interleukin-28B Genotype in Treatment Decision-Making in Recent Hepatitis C Virus Infection. Hepatology, 52(4), 1216-1224. [More Information]
  • Patterson, S., George, J., Strasser, S., Lee, A., Sievert, W., Nicoll, A., Desmond, P., Roberts, S., Locarnini, S., Bowden, S., et al (2010). Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut (English Edition): an international journal of gastroenterology and hepatology, 60(2), 247-254. [More Information]
  • Hebbard, L., George, J. (2010). The chicken or the egg: adipocytes and hepatic insulin resistance. Hepatology, 51(3), 1076-1079. [More Information]
  • Robotin, M., Kansil, M., George, J., Howard, K., Tipper, S., Levy, M., Phung, N., Penman, A. (2010). Using a population-based approach to prevent hepatocellular cancer in New South Wales, Australia: effects on health services utilisation. BMC Health Services Research, 10, 215-224. [More Information]

2009

  • Milner, K., van der Poorten, D., Xu, A., Bugianesi, E., Kench, J., Lam, K., Chisholm, D., George, J. (2009). Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology, 49(6), 1926-1934. [More Information]
  • Smith, B., George, J. (2009). Adipocyte-hepatocyte crosstalk and the pathogenesis of nonalcoholic fatty liver disease. Hepatology, 49(5), 1765-1767. [More Information]
  • Johnson, N., Sachinwalla, T., Walton, D., Smith, K., Armstrong, A., Thompson, M., George, J. (2009). Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology, 50(4), 1105-1112. [More Information]
  • Robotin, M., Kansil, M., Howard, K., George, J., Tipper, S., Dore, G., Levy, M., Penman, A. (2009). Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. Journal of Hepatology, 50(5), 990-998. [More Information]
  • Booth, M., Dobbins, T., Aitken, R., Denney-Wilson, E., Hardy, L., Okely, A., George, J., Sullivan, D., Cowell, C. (2009). Costs of managing conditions associated with obesity among Australian teenagers. Journal of Paediatrics and Child Health, 45(7-8), 448-456. [More Information]
  • van der Poorten, D., Milner, K., George, J. (2009). Effect of adipokines on liver disease in females. In Ichiro Shimizu (Eds.), Female Hepatology: Impact of female sex against progression of liver disease, (pp. 191-212). India: Research Signpost.
  • Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M., Bassendine, M., Spengler, U., Dore, G., Powell, E., Stewart, G., Booth, D., George, J., et al (2009). IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature Genetics, 41(10), 1100-1104. [More Information]
  • Johnson, N., St George, A., George, J. (2009). Impact of lifestyle modification on patients with chronic liver disease. Hot Topics in viral Hepatitis, 5(14), 17-22.
  • St George, A., Bauman, A., Johnston, A., Farrell, G., Chey, T., George, J. (2009). Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology, 50(1), 68-76. [More Information]
  • Wang, J., Leclercq, I., Brymora, J., Xu, N., Ramezani-Moghadam, M., London, R., Brigstock, D., George, J. (2009). Kupffer Cells Mediate Leptin-Induced Liver Fibrosis. Gastroenterology, 137(2), 713-723. [More Information]
  • Douglas, M., George, J. (2009). Molecular mechanisms of insulin resistance in chronic hepatitis C. World Journal of Gastroenterology, 15(35). [More Information]
  • Bhala, N., Usherwood, T., George, J. (2009). Non-alcoholic fatty liver disease. BMJ: British Medical Journal, 339(b2474), 513-514. [More Information]
  • George, J., Robotin, M. (2009). Overview: Hepatocellular carcinoma - the future starts now. Cancer Forum, 33(2), 83-87.
  • Phung, T., Pera, N., Farrell, G., Leclercq, I., Hou, J., George, J. (2009). Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis. International Journal of Molecular Medicine, 24, 171-180. [More Information]
  • Milner, K., Chisholm, D., George, J. (2009). The many faces of hepatitis C: liver disease and type 2 diabetes. Hepatology, 50(3), 668-670. [More Information]
  • Van Hazel, G., Pavlakis, N., Goldstein, D., Olver, I., Tapner, M., Price, D., Bower, G., Briggs, G., Rossleigh, M., Taylor, D., George, J. (2009). Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy. Journal of Clinical Oncology, 27(25), 4089-4095. [More Information]

2008

  • Poustchi, H., Mohamadkhani, A., Bowden, S., Montazeri, G., Ayres, A., Revill, P., Farrell, G., Locarnini, S., George, J., Malekzadeh, R. (2008). Clinical significance of precore and core promoter mutations in genotype D hepatitis B-related chronic liver disease. Journal of Viral Hepatitis, 15(10), 753-760.
  • van der Poorten, D., George, J. (2008). Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. Clinics in Liver Disease, 12(4), 805-824. [More Information]
  • St George, A., Bauman, A., Johnston, A., Farrell, G., Chey, T., George, J. (2008). Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. Hepatology, (doi:10.1111/j.1440-1746.2008.05694.x), 1-9. [More Information]
  • George, J., Talley, N., Segal, I., Weltman, M. (2008). Evaluating abnormal liver tests. In N Talley, I Segal, M Weltman (Eds.), Gastroenterology and Hepatology: a clinical handbook, (pp. 316-326). Australia: Elsevier.
  • Cua, I., Hui, J., Kench, J., George, J. (2008). Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology, 48(3), 723-731. [More Information]
  • Poustchi, H., Negro, F., Hui, J., Cua, I., Brandt, L., Kench, J., George, J. (2008). Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. Journal of Hepatology, 48(1), 28-34. [More Information]
  • Cua, I., George, J. (2008). Insulin resistance, adipocytokines and HCV infection: A missing link? Hepatology, 47, 760-761.
  • George, J., Liddle, C. (2008). Nonalcoholic fatty liver disease: Pathogenesis and potential for nuclear receptors as therapeutic targets. Molecular Pharmaceutics, 5(1), 49-59. [More Information]
  • van der Poorten, D., George, J. (2008). Nonalcoholic steatohepatitis is frequently acompanied by metabolic diseases: Reply to the Editor. Hepatology, 48(5), 1729. [More Information]
  • Johnson, N., Walton, D., Sachinwalla, T., Thompson, C., Smith, K., Ruell, P., Stannard, S., George, J. (2008). Noninvasive assessment of hepatic lipid composition: advancing understanding and management of fatty liver disorders. Hepatology, 47, 1513-1523. [More Information]
  • van der Poorten, D., Kenny, D., George, J. (2008). Prevalence of and risk factors for hepatitis C in Aboriginal and non-Aboriginal adolescent offenders. Medical Journal of Australia, 188(10), 610-614. [More Information]
  • Robotin, M., George, J., Supramaniam, R., Sitas, F., Penman, A. (2008). Preventing primary liver cancer: how well are we faring towards a national hepatitis B strategy? Medical Journal of Australia, 188(6), 363-365. [More Information]
  • Johnson, N., Sachinwalla, T., George, J. (2008). Reply: In Vitro Proton Magnetic Resonance Spectroscopy of Liver Tissue Informs In Vivo Hepatic Proton Magnetic Resonance Spectroscopy Studies. Hepatology, 48(3), 1016-1017. [More Information]
  • Wang, J., Brymora, J., George, J. (2008). Roles of adipokines in liver injury and fibrosis. Expert Review of Gastroenterology and Hepatology, 2(1), 47-57.
  • George, J., Denney-Wilson, E., Okely, A., Hardy, L., Aitken, R. (2008). The population distributions, upper normal limits and correlations between liver tests among Australian adolescents. Journal of Paediatrics and Child Health, 44(10), 579-585. [More Information]
  • Booth, M., George, J., Denney-Wilson, E., Okely, A., Hardy, L., Aitken, R., Dobbins, T. (2008). The population prevalence of adverse concentrations and associations with adiposity of liver tests among Australian adolescents. Journal of Paediatrics and Child Health, 44(12), 686-691. [More Information]
  • Yan, K., Guirgis, M., Dinh, T., George, J., Dev, A., Lee, A., Zekry, A. (2008). Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World Journal of Gastroenterology, 14(21), 3416-3420. [More Information]
  • van der Poorten, D., Milner, K., Hui, J., Hodge, A., Trenell, M., Kench, J., London, R., Peduto, A., Chisholm, D., George, J. (2008). Visceral fat: A key mediator of steatohepatitis in metabolic liver disease. Hepatology, 48(2), 449-457. [More Information]

2007

  • van der Poorten, D., Kenny, D., George, J. (2007). A new upper limit for alanine aminotransferase and risk factors for raised alt and hepatitis C in adolescents: a study of 439 male adolescent offenders on community orders. Journal of Gastroenterology and Hepatology, 22(Supplement 3), A344-A344.
  • Teoh, N., George, J. (2007). Abnormal Liver Function Tests. In N Talley, I Segal, M Weltman (Eds.), Gastroenterology and Hepatology: a clinical handbook. Australia: Elsevier.
  • Angulo, P., George, J., Marchesini, G., Bugianesi, E., Farrell, G., Day, C. (2007). Author's reply: Non-invasive markers of advanced histology in nonalcoholic fatty liver disease. Gastroenterology, 133(4), 1377-1378.
  • van der Poorten, D., George, J. (2007). Current and novel therapies for the treatment of nonalcoholic steatohepatitis. Hepatology International, 1(3), 343-354. [More Information]
  • Cua, I., Hui, J., Bandara, P., Kench, J., Farrell, G., McCaughan, G., George, J. (2007). Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology, 46(1), 66-73. [More Information]
  • van der Poorten, D., Kenny, D., Butler, T., George, J. (2007). Liver disease in adolescents: A cohort study of high-risk individuals. Hepatology, 46(6), 1750-1758. [More Information]
  • Razali, K., Thein, H., Bell, J., Cooper-Stanbury, M., Dolan, K., Dore, G., George, J., Kaldore, J., Karvelas, M., Li, J., Weltman, M., et al (2007). Modelling the hepatitis C virus epidemic in Australia. Drug and Alcohol Dependence, 91(39509), 228-235. [More Information]
  • London, R., George, J. (2007). Pathogenesis of NASH: Animal Models. Clinics in Liver Disease, 11(1), 55-74. [More Information]
  • Cua, I., George, J. (2007). Reply. Hepatology (Baltimore Md.), 46(6), 2051. [More Information]
  • Angulo, P., Hui, J., Marchesini, G., Bugianesi, E., George, J., Farrell, G., Enders, F., Saksena, S., Burt, A., Bida, J., Kench, J., et al (2007). The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 45(4), 846-854. [More Information]

2006

  • George, J. (2006). Angiopoietin-like proteins: Another player in the metabolic field. Journal of Hepatology, 44(4), 832-834. [More Information]
  • Bugianesi, E., Marchesini, G., Gentilcore, E., Cua, I., Vanni, E., Rizzetto, M., George, J. (2006). Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology, 44(6), 1648-1655. [More Information]
  • Salmond, S., George, J., Strasser, S., Batey, R. (2006). Hep573 study of complementary medicine for chronic hepatitis C. Journal Of Clinical Virology, 36(Supplement 2), S134-S135.
  • Chitturi, S., George, J. (2006). Hepatitis C and overweight. Hot Topics in viral Hepatitis, 2, 15-21.
  • Cua, I., George, J. (2006). Interpretation of abnormal liver tests in patients with diabetes. Diabetes Management Journal, 14, 30-31.
  • Cua, I., George, J. (2006). Interpretation of abnormal liver tests in patients with diabetes. Diabetes Management Journal, 14, 30.
  • Cua, I., Hui, J., Bandara, P., Kench, J., McCaughan, G., George, J. (2006). Is insulin resistance and liver injury in chronic hepatitis C associated with virus-specific alteration in the levels of serum adipocytokines? Journal of Gastroenterology and Hepatology, 21, A22-A22.
  • St George, A., Johnston, A., Bauman, A., Iverson, D., Tapsell, L., McCaughan, G., Strasser, S., McGrath, L., Green, J., Farrell, G., George, J. (2006). Lifestyle intervention in early liver disease: metabolic changes at 3 months. Journal of Gastroenterology and Hepatology, 21(Suppl. 4), A315.
  • Cua, I., Kwan, V., Henriquez, M., Kench, J., George, J. (2006). Long term suppressive therapy with pegylated interferon for chronic hepatitis C associated membranoproliferative glomerulonephritis. Gut (English Edition): an international journal of gastroenterology and hepatology, 55(10), 1521-1522. [More Information]
  • Leandro, G., Mangia, A., Hui, J., Fabris, P., Rubbia-Brandt, L., Colloredo, G., Adinolfi, L., Asselah, T., Jonsson, J., Smedile, A., George, J., et al (2006). Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology, 130(6), 1636-1642. [More Information]
  • Wang, J., Batey, R., George, J. (2006). Role of ethanol in the regulation of hepatic stellate cell function. World Journal of Gastroenterology, 12(43), 6926-6932. [More Information]
  • Poustchi, H., George, J., Farrell, G. (2006). The efficacy of a liver cancer screening program on cancer detection and patient survival. Journal of Gastroenterology and Hepatology, 21, A52-A52.

2005

  • Helbig, K., George, J., Beard, M. (2005). A novel I-TAC promoter polymorphic variant is functional in the presence of replicating HCV in vitro. Journal Of Clinical Virology, 32(2), 137-143. [More Information]
  • Bandara, P., George, J., McCaughan, G., Naidoo, D., Lux, O., Salonikas, C., Kench, J., Byth Wilson, K., Farrell, G. (2005). Antioxidant levels in peripheral blood, disease activity and fibrotic stage in chronic hepatitis C. Liver International, 25(3), 518-526. [More Information]
  • Perry, J., Poustchi, H., George, J., Farrell, G., McCaughan, G., Strasser, S. (2005). Current approaches to the diagnosis and management of hepatocellular carcinoma. Clinical and Experimental Medicine, 5(1), 1-13. [More Information]
  • Adams, L., Bulsara, M., Rossi, E., DeBoer, B., Speers, D., George, J., Kench, J., Farrell, G., McCaughan, G., Jeffrey, G. (2005). Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clinical Chemistry (Washington, DC), 51(10), 1867-1873. [More Information]
  • Kumar, U., Farrell, G., Kench, J., George, J. (2005). Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. Journal of Gastroenterology and Hepatology, 20(9), 1395-1400. [More Information]
  • Dela Pena, A., Leclercq, I., Field, J., George, J., Jones, B., Farrell, G. (2005). NF-kappa B activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology, 129(5), 1663-1674. [More Information]
  • Cua, I., George, J. (2005). Non-alcoholic fatty liver disease. British Journal of Hospital Medicine (London), 66(2), 106-111. [More Information]
  • Hui, J., George, J. (2005). Reply: Adiponectin – Tipping the scales from NAFLD to NASH. Gastroenterology, 128(2), 513-513.
  • Hui, J., George, J. (2005). Reply: Reduced plasma adiponectin: central obesity as an underestimated causative risk factor. Hepatology, 41, 401-402. [More Information]

2004

  • Hui, J., Hodge, A., Farrell, G., Kench, J., Kriketos, A., George, J. (2004). Beyond Insulin Resistance In Nash: Tnf-Alpha Or Adiponectin? Hepatology, 40(1), 46-54. [More Information]
  • Coverdale, S., Khan, M., Byth Wilson, K., Lin, R., Weltman, M., George, J., Samarasinghe, D., Liddle, C., Farrell, G., Kench, J., Crewe, E. (2004). Effects Of Interferon Treatment Response On Liver Complications Of Chronic Hepatitis C: 9-Year Follow-Up Study. American Journal of Gastroenterology, 99(4), 636-644.
  • McCaughan, G., George, J. (2004). Fibrosis Progression In Chronic Hepatitis C Virus Infection. Gut (English Edition): an international journal of gastroenterology and hepatology, 53(3), 318-321.
  • Hui, J., Farrell, G., Kench, J., George, J. (2004). High sensitivity C-reactive protein values do not reliably predict the severity of histological change in NAFLD. Hepatology, 39(5), 1458-1459. [More Information]
  • Sud, A., Hui, J., Farrell, G., Bandara, P., Kench, J., Fung, C., Lin, R., Samarasinghe, D., Liddle, C., McCaughan, G., George, J. (2004). Improved Prediction Of Fibrosis In Chronic Hepatitis C Using Measures Of Insulin Resistance In A Probability Index. Hepatology, 39(5), 1239-1247. [More Information]
  • Kwan, V., George, J. (2004). Liver Disease Due To Parenteral And Enteral Nutrition. Clinics in Liver Disease, 8(4), 893-913, ix-x.
  • Chitturi, S., Farrell, G., George, J. (2004). Non-Alcoholic Steatohepatitis In The Asia-Pacific Region: Future Shock? Journal of Gastroenterology and Hepatology, 19(4), 368-374.
  • Zeuzem, S., Diago, M., Gane, E., Reddy, K., Pockros, P., Prati, D., Shiffman, M., Farci, P., Gitlin, N., O'Brien, C., George, J., et al (2004). Peginterferon Alfa-2a (40 Kilodaltons) and Ribavirin in Patients With Chronic Hepatitis C and Normal Aminotransferase Levels. Gastroenterology, 127(6), 1724-1732.

2003

  • Shao, R., Shi, Z., Gotwals, P., Koteliansky, V., George, J., Rockey, D. (2003). Cell and molecular regulation of endothelin-1 production during hepatic wound healing. Molecular Biology of the Cell, 14(6), 2327-2341.
  • Coverdale, S., Samarasinghe, D., Lin, R., Kench, J., Byth Wilson, K., Khan, M., Crewe, E., Liddle, C., George, J., Farrell, G. (2003). Changes in Antipyrine Clearance and Platelet Count, but Not Conventional Liver Tests, Correlate With Fibrotic Change in Chronic Hepatitis C: Value for Predicting Fibrotic Progression. American Journal of Gastroenterology, 98(6), 1384-1390.
  • Kumar, D., Wallington-Beddoe, C., George, J., Lin, R., Samarasinghe, D., Liddle, C., Farrell, G. (2003). Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hapatitis c in a clinic setting. Medical Journal of Australia, 178(6), 267-271.
  • Hui, J., Sud, A., Farrell, G., Bandara, P., Byth Wilson, K., Kench, J., McCaughan, G., George, J. (2003). Insulin resistance is associated with chronic Hepatitis C and virus infection fibrosis progression. Gastroenterology, 125(6), 1695-1704.
  • Chitturi, S., George, J. (2003). Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Current Gastroenterology, 5(1), 18-25.
  • George, J. (2003). Invited Book Review – Hepatitis C: An Australian perspective. Eds. N Crofts, G Dore and S Locarnini. Internal Medicine Journal, 33(1), 64-64.
  • George, J., Pera, N., Phung, T., Leclercq, I., Hou, J., Farrell, G. (2003). Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. Journal of Hepatology, 39(5), 756-764.
  • Hui, J., Kench, J., Chitturi, S., Sud, A., Farrell, G., Blyth, K., Hall, P., Khan, M., George, J. (2003). Long term outcomes of cirrhosis in nonalcoholic steatohepatitis compares with hepatitis c. Hepatology, 38(2), 420-427.
  • Perry, J., Strasser, S., George, J., Farrell, G., McCaughan, G. (2003). Pharmacotherapy of hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 4(12), 2175-2185.
  • Chitturi, S., Farrell, G., George, J. (2003). Reply: Iron and HFE mutations in nonalcoholic steatohepatitis: Innocent bystanders or accessories to the crime? Gastroenterology, 125(2), 616-616.
  • Lee, D., Chitturi, S., Kench, J., George, J., Fuller, S., Bradstock, K., Lin, R., Wong, K., Young, N. (2003). Transjugular liver biopsy effecting changes in clinical management. Journal of Medical Imaging and Radiation Oncology, 47(2), 117-120. [More Information]

2002

  • Hui, J., George, J., Liddle, C., Lin, R., Samarasinghe, D., Crewe, E., Farrell, G. (2002). Changes in Serum Albumin During Treatment of Chronic Hepatitis B With Lamivudine: Effects of Response and Emergence of Drug Resistance. American Journal of Gastroenterology, 97(4), 1003-1009.
  • Singal, D., George, J. (2002). Chronic hepatitis C. Australian Doctor.
  • Teoh, N., George, J. (2002). Evaluating patients who have abnormal liver tests. Medicine Today, 3(10), 58-67.
  • Chitturi, S., George, J., Ranjitkumar, S., Kench, J., Benson, W. (2002). Exchange Transfusion for Severe Intrahepatic Cholestasis Associated With Sickle Cell Disease. Journal of Clinical Gastroenterology, 35(4), 362-363.
  • Alonso, C., George, J., Pesce, C., Bissell, D., Kornblihtt, A. (2002). Fibronectin transcription in liver cells: promoter occupation and function in sinusoidal endothelial cells and hepatocytes. Biochemical and Biophysical Research Communications, 295(5), 1077-1084.
  • Hui, J., Kench, J., Farrell, G., Lin, R., Samarasinghe, D., Liddle, C., Byth, K., George, J. (2002). Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. Journal of Gastroenterology and Hepatology, 17(8), 873-881.
  • Chitturi, S., Le, V., Kench, J., Loh, C., George, J. (2002). Gliclazide-Induced Acute Hepatitis with Hypersensitivity Features. Digestive diseases and sciences, 47(5), 1107-1110.
  • Hui, J., Farrell, G., Lin, R., Samarasinghe, D., Liddle, C., George, J., Kench, J., Byth, K. (2002). Hepatic Steatosis in Chronic Hepatitis C Infection. Journal of Gastroenterology and Hepatology, 17(8), 873-881.
  • Kumar, S., Farrell, G., Fung, C., George, J. (2002). Hepatitis C Virus Genotype 3 is Cytopathic to Hepatocytes: Reversal of Hepatic Steatosis after Sustained Therapeutic Response. Hepatology, 36(5), 1266-1272.
  • Chitturi, S., George, J. (2002). Hepatotoxicity of Commonly Used Drugs: nonsteroidal Anti-Inflammatory Drugs, Antihypertensives, Antidiabetic Agents, Anticonvulsants, Lipid-Lowering Agents, Psychotropic Drugs. Seminars in Liver Disease, 22(2), 169-183.
  • Chitturi, S., Weltman, M., Farrell, G., McDonald, D., Liddle, C., Samarasinghe, D., Lin, R., Abeygunasekera, S., George, J. (2002). HFE Mutations, Hepatic Iron, and Fibrosis: Ethnic-Specification Association of NASH with C282Y but not with Fibrotic Severity. Hepatology, 36(1), 142-149.
  • Chitturi, S., Abeygunasekera, S., Farrell, G., Holmes-Walker, J., Hui, J., Fung, C., Karim, R., Lin, R., Samarasinghe, D., Liddle, C., Weltman, M., George, J. (2002). NASH and Insulin Resistance: Insulin Hypersecretion and Specific Association with the Insulin Resistance Syndrome. Hepatology, 35(2), 373-379.
  • Chitturi, S., Farrell, G., Frost, L., Kriketos, A., Lin, R., Liddle, C., Samarasinghe, D., George, J. (2002). Serum Leptin in NASH Correlates with Hepatic Steatosis but not Fibrosis: A Manifestation of Lipotoxicity? Hepatology, 36(2), 403-409.
  • Farrell, G., Phung, T., Ip, E., Dela Pena, A., Robertson, G., Pera, N., George, J., Leclercq, I. (2002). Sources of oxidant stress in fatty liver disorders. Interactive mechanisms, and relevance to fibrosing steatohepatitis. AASLD Single Topic Conference NASH – Nonalcoholic Steatohepatitis.
  • Wong, V., Fu, A., George, J., Cheung, N. (2002). Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clinical Endocrinology, 56(6), 793-798.

2001

  • Chitturi, S., Hui, J., Salisbury, E., Mitchell, D., George, J. (2001). Abdominal pain in an intrauterine contraceptive devise user. Postgraduate Medical Journal, 77, 602-610.
  • Phung, T., Farrell, G., Robertson, G., George, J. (2001). Antioxidant therapy with vitamin E ameliorates hepatic fibrosis in MCDD-associated NASH. Asia Pacific Digestive Week 2001, : World Scientific Publishing.
  • Chitturi, S., Abeygunasekera, S., Fung, C., Samarasinghe, D., Lin, R., McDonald, D., Weltman, M., Farrell, G., George, J. (2001). Haemochromatosis gene mutations, hepatic iron content and nonalcoholic steatohepatitis. Hepatology, 19, 1768-1778.
  • Leclercq, I., George, J., Farrell, G., Robertson, G., Field, J. (2001). Leptin is an essential mediator of hepatic fibrogenesis and liver regeneration in chronic CCl4-induced liver injury. Asia Pacific Digestive Week 2001, : World Scientific Publishing.
  • Pera, N., Phung, H., Leclercq, I., Farrell, G., George, J. (2001). Oxidative stress and the evolution of hepatic fibrogenesis in a rodent model of nonalcoholic steatohepatitis. Asia Pacific Digestive Week 2001, : World Scientific Publishing.
  • Coverdale, S., Samarasinghe, D., Lin, R., Liddle, C., George, J., Farrell, G., Kench, J., Byth, K., Khan, M., Crewe, E. (2001). Prediction of histological progression in chronic hepatitis C. Asia Pacific Digestive Week 2001, : World Scientific Publishing.
  • George, J., Hui, J., Farrell, G., Lin, R., Samarasinghe, D., Kench, J. (2001). Predictors for steatosis and fibrosis in chronic hepatitis C. Journal of Hepatology, 34, 153-153.
  • Farrell, G., Liddle, C., Samarasinghe, D., Lin, R., George, J., Chitturi, S., Frost, L. (2001). Serum Leptin: An independent predictor of hepatic steatosis but not fibrotic severity in nonalcoholic steatohepatitis. Hepatology, 34, 752-752.
  • Pera, N., Phung, H., Leclercq, I., Farrell, G., George, J. (2001). The role of oxidative stress in the evolution of hepatic fibrogenesis in a rodent model of nonalcoholic steatohepatitis. The American Association for the Study of Liver Diseases 52nd Annual Meeting, : World Scientific Publishing.
  • Pera, N., Phung, H., Leclercq, I., Farrell, G., George, J. (2001). This role of oxidative stress in the evolution of hepatic fibrogenesis in a rodent model of nonalcoholic steatohepatitis. Hepatology, 34, 1132-1132.
  • Bissell,, D., Roulot, D., George, J. (2001). Transforming growth factor B and the liver. Hepatology, 34(5), 859-867.
  • Phung, T., Farrell, G., Robertson, G., George, J. (2001). Vitamin E but not glutathione precursors ameliorates hepatic fibrosis in experimental NASH. Journal of Gastroenterology and Hepatology, 16.
  • Phung, T., Farrell, G., Robertson, G., George, J. (2001). Vitamin E but not glutathione precursors inhibits hepatic fibrosis in experimental NASH exhibiting oxidative stress and mitochondrial abnormalities. Hepatology, 34, 756-756.

To update your profile click here. For support on your academic profile contact .